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Mononuclear phagocytes increasingly appear to have a central regulatory 
role in governing in~lammatory and immune responses. The concept of macrophage 
activation dates from Metchnikoff who noted that mononuclear phagocytes from 
animals resistant to bacterial challenge had perfected their powers of 
phagocytosis and microbicidal destruction. This classical view places the 
macrophage in the efferent part of the immune system. More recently it has been 
shovn that macrophagcs are cruciallY involved in the regulation of lymphocyte 
f~~ction, thus playing a~ important role in the afferent part of the imm~~e 
system. Chapter 1 briefly summarizes the role of macrophages in immunity, the 
mechanisms leading to macrophage activation and alterations in macrophage 
metabolism and chemistry that accompany these cha~ges. 
Multiple signals from the extracellular milieu act on macrophages to 
regulate activation. In turn, the numerous secretory products of macrophages 
act on the environment. Among these products are arachidonic acid derived 
metabolites (chapter 2) which play a profound role in dictating the progression 
of immune events. For example, various hydroxyeicosatetraenoic acids and 
leukotriene B4 are extremely potent in regulating the functions of neutrophile, 
the hallmark of acute inflammatory mechanisms. In addition, specific 
prostaglandins have been shown to modulate the function of macrophages and 
suppress a variety of inflammatory or immune related processes. For example. 
earlier observations in our laboratory showed that prostaglandins of the 
E-series inhibited the development of the macrophage mediated proliferative 
component of an inflammatory reaction. They further indicated that this 
inhibition was realized via stimulation of macrophage cyclic AMP synthesis. In 
chapter 3 the mechanisms, by which alterations in cyclic AMP content a~fect 
macrophage activity are briefly summarized. 
The findings described in the previous paragraph led to the experiments 
described 1n this thesis. which are aimed at unravelling the interaction of 
various arachidonic acid oxygenation products with regard to the regulation of 
macrophage activity. 
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CHAPTER 1 • MA.CROPHAGES 
1 INTRODUC'XION 
The term -mononuclear phagocytes- is generally used to re~er to a very 
large family of phagocytic cells which are all derived from the bone marrow or 
blood monocytes98 , although a self-renewing population of tissue macrophages has 
been postulated as we11 61 (figure 1 ). These cells are long-lived and, in 
contrast to another phagocyte, the neutrophil granulocyte, they have the 
capacity to differentiate into a variety of macrophages or macrophage-like cells 
in response to different activating signals. A typical macrophage does not 
exist. Originally characterized as phagocytic cells172 , macrophages have over 
the last two decades been recognized as omnipotent cells, making up the 
~;~11 
'•• I 
·. ~ 
MONOBLAST PROMONOCYTE ~ 
.... , ~ 
;~~ 
TISSUE MACROPHAGE 
EXUDATE MACROPHAGE 
Figu~e 1. Origin and peroxidatic activity of macrophages. Peroxida:ic activity 
in the nuclea::o envelope (monoblast, promonocyte aJ".d tissue macrophage), ;Jeroxi-
Case positive granules (all except tiscue macrophage), Golgi apparatus (promono-
cyte) ~~d endoplasmic reticulum (monoblast, promonocyte ~~d tissue macrophage). 
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Table 1. Secretory products of macrophages. 
-hydrolytic enzymes (a.o. lysozyme) 
-oxygen metabolites 
-several complement components 
-interferon 
-interleukin-1 
-fibroblast stimulating factor 
-cr2-macroglobulin 
-platelet-activating factor 
-eicosanoids 
-thymidine 
-monocytopoiesis increasing factor {FIM) 
non-specific branch of the immune system180 . Not only does the macrophage 
ingest and kill microbes, it also plays a key role in initiating an immune 
reaction and subsequently modulates the immune responses. Additionally, 
macrophages were found to selectively and efficiently lyse tumour cells8 · 124 
The efficiency of the macrophage primarily is based on the release of an 
enormous battery of secretory products (table 1 )77 • 114 • 134 . Most of these 
products are either involved i~ the defense against microorganisms, the 
destruction of damaged or neoplastic cells, the stimulation or inactivation of 
various enzyme systems or the modulation of imm~~e responses. 
2 FUNCTION 
In spite of the danger of oversimplifying the diverse functional aspects of 
macrophages. in following paragraphs the mechanisms involved in 
phagocytosis, cytotoxicity and immunoregulaticn will be discussed seperately; 
in fact all these functions are interrelated. 
- 11 -
Phagocytosis and bactericidal activity. 
Mononuclear phagocytes bind and e~ficiently destroy a variety of 
microorga~isms. Phagocytosis is a tvo step process 114 . The ~irst step involves 
attachment of the particle to the macrophage membrane. During the second step. 
the surface membrane moves over the particle until it is covered. For an 
efficient phagocytosis the participation of Fe- (immune complexes) and C3b-
(complement cleavage products) receptors are required77 • 134 . Opsonization of 
the antigen or particle with antibodies greatly facilitates binding as well as 
engulfment, opsonization with complement factors only enhances the actual 
binding215 . Fe- or C3b-mediated activation of macrophages 
enzymes 133 and various rapid secretion of lysosomal 
arachidonic acid oxygenation metabolites206 . 
is accompanied by a 
mediators including 
The signi~icance of both events 
will be discussed in more detail in other parts o~ this chapter. 
Phagocytosis is ~allowed by a metabolic burst with an increase of oxygen 
utilization. The oxygen is used for the production of superoxide, in order to 
produce hydrogen peroxide. hydroxyl radicals and other oxygen radicals such as 
singlet oxygen148 . Studies using cell lines which arc defective ~or oxygen 
metabolism indicated that hydrogen peroxide is primarily responsible for 
intracellular killing of phagocytosed bacteria63 •247 . After reconstitution with 
a hydrogen peroxide generating system the bactericidal activity of these 
defective cells vas restored. 
A second effector mechanism of macrophages involves their capacity to 
secrete a variety of hydrolytic enzymes, which may enha~ce killing of microbes. 
Macrophages contain a number of enzymes with dif~erent specificities and 
f~~ctions. 
Lysozyme (muramidase), a cationic protein with a hydrolase activity, may be 
considered a typical phagocytic enzyme 11 •108 
the living monocyte it is only released 
However, while 
by the dying 
it is secreted by 
granulocyte 119 . 
Mononuclear phagocytes have a very low intracellular lysozyme conte~t. 
nevertheless they continuously secrete large amounts of lysozyme, the rate of 
secretion being similar in resident, quiescent and activated or elicited 
macrophages 12 . Lysozyme secretion is a use~ull para~eter in assess1ng the 
viability o~ macrophages in culture since the rate of secretion remains very 
constant. The measurement of lactate dehydrogenase, a cytoplasmic enzyme. 
activity 1n supernatants can be used for the same purpose as. under normal 
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culture conditions, it is not released from the cells. 
Lysoso~ hydrolases originally were found in phagosomes where they serve 
the purpose of intracellular digestion54 . 
endocytic vacuoles and lysosomes. 
Phagosomes arise 
Some fiftheen years ago261 
from the fusion of 
it was found that 
macrophages release large quantities of lysosomal enzymes in response to 
phagocytic stimuli. It was also established that the rate of stimulated release 
reflects the degree of activation of the ce1165 . The fact that the amounts of 
lysosomal hydrolases excreted, exceed the amounts which present 
intracellularly, indicate that the release is based upon ~ synthesis. 
Indeed it could be shown that cycloheximide, a protein synthesis inhibitor, 
almost completely blocked the release224 . 
Neutral proteinases play a major role in various inflammatory processes and 
may effectively destroy constituents of the connective tissues. The best-known 
neutral proteinase is plasminogen activator which transformes the inactive 
precursor plasminogen into the fibrinolytically active plasmin. Plasmin also 
has the capacity to activate the complement and kinin systems149 . Only 
activated macrophages release neutral proteinases, which is the reason why 
plasminogen activator release is often used as a parameter to distinguish 
between resident and stimulated or elicited macrophages225 . 
Cytotoxicity. 
Considerable interest has been focussed on the cytotoxic activity of 
macrophages, a function which is believed to play a significant role in 
resistance to infection, tumour reJection ~~d certain autoimmune reactions. 
Although the exact mechanisms which underlie cytotoxicity are beyond the scope 
of this thesis ~~dare extensively reviewed elsewhere4 · 166 •200 •251 . some aspects 
of cytotoxicity will be discussed in the following section. 
Two distinct modes of action can be distinguished by which macrophages 
destroy tumour cells2 . The first of these is the rapid, highly specific lysis 
of antibody-coated targets in which neoplastic as well as non-neoplastic cells 
can be destroyed. Evidence from murine systems strongly indicates recognition 
of antibody-coated targets is mediated largely by Fc-receptors on the 
macrophages 185 a~d that secretion of hydrogen peroxide is a major lytic 
The second mode of action is a slow, contact-dependent 
cytotoxicity, which is selective for neoplastic targets and not dependent on the 
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presence of antibodies. The mechanisms by which activated macrophages injure 
neoplastic cells are incompletely defined at present. A possible factor may 
involve premature induction of a fatal cycle of tumor cell division. The lethal 
result would be the generation of an aberrant population of tumour cells with a 
reduced content of DNA 56 . Also, secretion of a neutral proteinase, termed 
cytolytic factor, that effectively lysis neoplastic cells 1 • 143 is considered to 
be one of the major events in macrophage mediated cytotoxicity. 
macrophage derived factors which have 
thymidine242 , arginase59 , cachectin18 and 
related to lymphotoxin73. 
Immunoregulation 
been described as cytotoxic 
a recently defined198 soluble 
Other 
include 
factor. 
Recently considerable advances have been made in understanding the role of 
macrophages in the regulation of the immune response, whereby the attention has 
been focussed on the effects of secretory products, including monokines and 
eicosanoids. Macrophages are essential for the initiation and maintenance of a 
variety of lymphocyte effector cell functions (table 2). However, macrophagcs 
can act as -helper cells- during initiation of an immune response, and as 
-suppressor cells- at a later stagc 101 
Table 2. Macrophages act as accesory cells in: 
-antigen induced T-cell proliferation 211,243 
-lectin induced T-cell proliferation 145.181.222 
-interactions between T-and B-cells in antibody formation 199.241 
-interactions with T-cells in cellular immunity reactions 107,174,250 
-interactions with B-cells and polyclonal stimuli 212,270 
-mixed lymphocyte reactions 57,99 
-anti-tumour imm~~ity 248 
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Antigen presentation by macrophages is a prerequisite for all aspects of 
antigen-specific T lymphocyte responses, including T cell memory39 • 186 •25°. The 
proliferative response of T cells to antigens has been one of the systems most 
extensively employed for studying macrophage-lymphocyte interactions. Such 
a~tigens include synthetic amino acid polymers and polypeptide hormones as well 
as xenogeneic antibodies. An example of the induction of antigen-specific 
proliferation ofT cells from a study by Huber and Stingl 135 is given below. In 
this experiment purified T cells were sensitized to rabbit IgG pulsed human 
macrophages. Secondary proliferative responses were subsequently induced by 
restimulation of sensitized T cells with antigen-pulsed or native macrophages. 
A proliferative response could only be induced with autologous, antigen-pulsed 
macrophages. Furthermore, depleting the macrophages of the HLA-DR+ cells 
completely abolished the observed responses. This second finding emphasizes the 
importance of the major histocompatibility gene complex (HLA in man, H-2 in 
mice)168. 
The major histocompatibility system codes for a large group of surface 
glycoproteins 14 •238 . One type of glycoproteins corresponds serologically to the 
HLA-D region associated antigens in man and the I region associated antigens in 
rodents. The~e antigens, which were indentified on macrophages, B lymphocytes 
and on a few activated T cells250 • are identical to those structures on the 
surface of macrophages which control cooperation with T cells40 •50 . Thus. for 
effective T cell-macrophage collaboration in man, two essential features are 
required: (I) that the proliferating T cell the macrophage are 
histocompatible. share the HLA-D/DR region; (II) that the phagocyte bears the 
region associated ~~tigens (HLA-D/DR) of the major histocompatibility complex. 
Secretory products. Among the secretory products of macrophages that 
participate in immunoregulation109 monokines and eicosanoids26 take the most 
prominent positions. As eicosanoids will be discussed in detail in chapter 2, 
the following paragraphs will only deal with the mode of action of mo~okines. 
One of the most important lymphocyte stimulatory molecules is lymphocyte 
activating factor (LAF), 
after Gery's observation, 
first clearly 
Schrader 227 
demonstrated by Gery et al. 102 Shortly 
reported that macrophage supernatants 
could also stimulate the development of ~~tibody-secreting B cells. The factor 
in the supernat~~t was termed B cell activating factor (BAF). Since studies 
the chemical nature revealed that LAF and BAF were identical 152 , 26 9, it 
on 
was 
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suggested that the term interleukin-1 (IL-1) be introduced to designate the 
molecule, a polypeptide with a molecular weight between 13.000-16.000 dalton. 
Major effects of IL-1 are to stimulate proliferation of T lymphocytes, 
augment their response to mitogens, and promote secretion of a very potent 
lymphocyte stimulant, interleukin-2 (IL-2) (Table 3). Although from the 
functions enlisted in table 3 one might conclude that IL-1 is the principal 
immunoregulatory molecule. some caution must be taken. IL-1 indeed is capable 
of stimulating antigen induced T cell proliferation but only on the condition 
that macrophages are present in sufficient amounts to assure proper antigen 
presentation194 · 272 . 
Table 3. Effects of interleukin-1 
A. Immune system related effects 
-stimulation ofT lymphocute proliferation 167 
-induction of IL-2 release 84 
-T lymphocyte surface alteration 15.202 
-induction of cytotoxic lymphocytes 85 
-stimulation of Natural Killer cells 66 
-enhancement of glucocorticoid resistance 175 
-enha~cement of the antibody response 165 
-stimulation of antigen activated T-helper cells 147 
-induction of prostaglandin :;~.ynthecis 31 ,68 
B. Non-immunological effects 
-induction of fever 213 
-stimulation of acute phase protein synthesis 146 
-muscle breakdown 13 
-neutrophil granulocyte activation and migration 151,223 
-fibroblast, chondrocyte a~d synoviocyte stimulation 112,201.271 
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Also, the induced proliferation is not an effect of IL-1 per se, but seems 
to be mediated via IL-255 • 190 , whereas the IL-1 induced immunoglobulin release 
is dependent on the presence of T cells and macrophages 165 . Finally, 
interactions between IL-1 and arachidonic acid oxygenation metabolites, 
discussed below. could provide a fine tuning mechanism by which the immune 
system could limit its own activity 
production is stimulated by metabolites of 
(figure 2). The 
the lipoxygenase 
discovery that IL-1 
pathway69 is of 
considerable interest, especially in the light of the results presented in this 
thesis. Cyclooxygenase derived metabolites of arachidonic acid on the other 
hand, have been shown to depress IL-1 release as well as the effects of IL-1 on 
lymphocytes42 •123 . 
Ag presen-
tation 
Ag 
LYMPHO-
CYTES 
act. 
L_ ____ I_L_--2--+ LYMPHO-
r + CYTES 
MAF 
Cytotoxicity 
Proliferation 
Immunoglobulin 
secretion 
Tumoricidal 
Bactericidal 
activity 
Figure 2. Interaction between eicosanoids and interleukin-1 in the regulation of 
macrophage activity. Abbreviations used for antigen (Ag). interleukin-1 (IL-1 ), 
interleukin-2 (IL-2), leukotriene c 4 (LTC4 ), macrophage activating factor (MAF) 
and prostaglandin E2 (PGE2 ). 
- 17 -
:5 ACTIVATION 
Macrophage activation is neither a single alteration nor a fixed set of 
alte"ations in macrophage metabolism. Rather, activation is better viewed as 
competence to carry out one complex function or another and, as such, depends on 
expression of multiple capacities, which may vary depending on the function. 
Thus. macrophages activated for tumoricidal activity are not necessarily 
activated for microbicidal function, while macrophages activated for 
microbicidal f~~ction are not necessarily activated for tumoricidal 
function 153 • 183 . For the sake of clearness a distinction has to be made between 
activation and state of activity of macrophages. Evidence has emerged that 
macrophages become activated by passing sequentially through a series of defined 
stages. These stages may be induced in vivo and in vitro, and each is 
operationally defined by how it is induced and how it must be further stimulated 
to express full activation125 · 171 •247 . Since thisphenomenon is excellently 
Table 4. Factors used for macrophage activation 
in vitro: in vivo: 
-latex beads/zymosan -serum 
-microorganisms -microorganisms 
-endotoxin -endotoxin 
-concanavalin A -thioglycollate 
-phorbol myristate acetate -carrageenan 
-complement factors -protease peptone 
-immune complexes -adjuvant 
-lymphokines 
-ionophore 
-arachidonic acid 
Note: the stimuli applied in vivo can be also used in vitro 
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reviewed elsewhere4 and is beyond the scope of this thesis, the following 
paragraphs will be restricted to a brief comparison between resident and 
elicited/inflammatory macrophages. 
Several eliciting agents have been shown in CA~erimental animals to recruit 
populations of activated, inflammatory macrophages, and in vitro culture 
experiments have demonstrated that quiescent, resident tissue macrophages can be 
induced to differentiate in response to particulate and soluble factors 
(table 4). When an inflammation is induced in the peritoneal cavity, there is 
an increased influx o~ bone marrow derived monocytes from the peripheral blood 
into the peritoneal cavity, which differentiate into inflammatory macrophages at 
the site of inflammation. Inflammatory macrophages differ in numerous ways from 
resident tissue macrophages61 They are larger and more irregular in shape. In 
addition, their surfaces are rougher and show more prominent ridgelike 
processes. In inflammatory macrophages the lysosomal apparatus is stimulated, 
large lysosomes and an intense deposition of fat droplets in the vicinity of 
lysosomes can be observed75 . 
resident ~~d inflammatory 
distribution of peroxidase 
Characteristic differences are found between 
macrophages 
activity61 
with respect to the 
Resident macrophages 
intracellular 
contain a 
peroxidase activity which is located in the rough endoplasmic reticulum and the 
nuclear envelope. In contrast, in inflammatory macrophages the peroxidase is 
located in granules Which are known to fuse with phagosomes as a result of which 
peroxidase is released into these vesicles. 
In table 5 changes in biochemical parameters of inflammatory macrophages in 
comparison with resident macrophages are listed. Noteworthy most alterations 
are increases with one major exception: the prostaglandin synthetase system and 
the herewith associated intracellular cAMP content. However. it must be 
emphasized that inflammatory macrophages respond to a second, in vitro stimulus 
with an enhanced production of prostaglandins followed by a rapid increase in 
intracellular cAMP content. The significance of this phenomenon will be 
discussed in extenso elsewhere in this thesis. 
Finally, the way in which the peritoneal exudate is induced and the nature 
of the inducing agent itself may change the properties of the macrophage 
population. Support for this statement car. be found in the results of studies 
using macrophages obtained from dialysis bags of patients on continuous 
ambulatory peritoneal dialysis30 . Using this technique for the treatment of 
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humans with a renal disease; the population of macrophages in the peritoneal 
cavity is renewed every six hours. Therefore it is justified to denominate the 
macrophages obtained from the dialysis fluid as elicited. However with respect 
to functional aspects, in terms of cyclic AMP content and responsiveness to 
prostaglandins these macrophages did not show characteristics of inflammatory 
cells. 
Table 5. Biochemical changes induced by stimulation of macrophages 
Parameter 
lysosomal enzyme release 
plasminogen activator release 
interleukin-1 release 
production of reactive o2 metabolites 
Ia-antigen expression 
alkaline phosphodiesterase activity 
adcnylate cyclase sensitivity 
lysozyme release 
c-AMP content 
prostaglandin production 
phosphulipase-A2 activity 
cyclooxygenase activity 
5'-nucleotidase activity 
Effect Reference 
65 
118 
131 
197 
46 
76 
78 
225 
78 
23 
136 
244 
136 
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CHAPTER 2. EICOSANOIDS 
1 INTRODUCXION 
Few areas of biological research have ever expa~ded as rapidly as that 
relating to the eicosanoicis. Eicosanoids is the general term used for the 
metabolites which are derived via oxidative metabolism of the fatty acid 
arachidonic acid. They include prostaglandins, thromboxanes, leukotrienes, 
lipoxina and other oxygenated compounds. 
Although the existence of prostaglandins and lcukotrienes already was 
described in the 1930s by von Eulcr83 and Fcldbcrg86 , the true importance of 
these mediators could only be assessed after elucidation of their structure and 
of the pathways involved in the biosynthesis of these substances. In 1964 this 
was independently realized for prostaglandins by a Swedish and Netherlands 
group 16 •71 Platelet aggregating activity of intermediates in the prostaglandin 
synthetase pathway which could not be explained with the effects of the then 
known prostaglandins led to the discovery of thromboxanes 117 . Shortly after, in 
1976, it was established that blood vessels could release a prostanoid which 
showed ef~~cts opposite to those of thrombox~~e. The newly found metabolite was 
termed prostacyclin 142 . In the meanwhile it was shown that non-steroidal 
anti-inflammatory drugs (e.g. aspirine) inhibit cyclooxygenase. the enzyme 
the conversion of arachidonic acid into which is rcsponsib~e for 
prostaglandins253 . Before being converted by cyclooxygcnase, arach1donic acid 
has to be liberateC from phospholipid pools, an event which appearcC to be 
blocked by corticosteroids 130 . Since pronounced diffcrencez 1n the 
anti-inflammatory cf:'ects of: corticosteroids and non-steroidal a:ltl-inflamrr,ato'y 
drugs can be o'::serveC. it see:ned conceivable that arachidonic acid generates an 
adC.itional inflam~atory meC.ia~or via a mech~~ism which 1s not dependent on 
cyclooxygenase activity. InCeed, it was shown ~hat arachiCon~c acid can be 
converted by a lipoxyeenase in "to lcukotrienec32 , come of which p:!'ovec 'to be 
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constituents of slow reacting substance of anaphylaxis (SRS-A) 220 . The ultimate 
finding in the domain of biologically active derivatives of arachidonic acid was 
the recent discovery of a new group of compounds, the lipoxins2 34 . 
2 BIOSYNTHESIS AND STRUCTURE 
Arachidonic acid liberation 
The liberation of unesterified archidonic acid from cellular phospholipids 
is considered to be the prerequisite for the synthesis and secretion of 
eicosanoids155 . Although there is not full agreement on which phospholipases 
are involved. the maJor route of phospholipid degradation is thought to be 
catalysed by phospholipase A2
138 Phospholipase A2 activity is dependent on 
three distinct, yet related factors: (a) availability of intracellular ca2+, 
(b) activity of lipocortin and (c) intracellular cAMP content (figure 1). Since 
phospholipase A2 activity is ca
2+ dependent an influx of Ca2+. as c~~ be 
achieved with the Ca-ionophore A23187, will enhance arachidonic acid liberation 
production252 . Physiologically, the resulting in a stimulation of eicosanoid 
intracellular availability of ca2 + is dependent on the turnover of phosphatidyl 
inositol 173 . Conversion of phosphatidyl inositol, catalysed by phospholipase C, 
yields inositol phosphates and phosphatidic acid. These products are thought to 
be essential for both the mobilisation of intracellular ca2 + stores =d tho 
influx of ca2 + from tho extracellular milieu21 . Both phospholipase A2 =d 
phospholipase c ~' inhibited by a polypeptide, termed lipocortin93 . Tho name 
lipocortin originated from observations that the synthesis of this protein which 
reduces lipid metabolism, was induced by corticosteroids92 •127 . Macrophages 
react very rapidly to corticosteroids. and they may be unusual in that 
lipocortin synthesis is not induced by corticosteroids (except as a later, 
secondary event) but rather that the steroids induce a protein synthesis 
dependent release of stored lipocortin20 . Once the lipocortin is released, the 
macrophages are no longer responsive to dexamethason until more protein is made; 
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Figure 1. In~erac~ions between lipocor~in, Ca2+ and cyclic AMP: 
phospholipase A2 activi~y. 
effec~s on 
they are. however. responsive ~o added lipocor~in45 . Lipocortin is inac~ivated 
by phosphoryla~ion, which is carried out by ~yrosine kinase. Tyrosine kinase 
itself is subjec~ to regulation by two serine kinazes, protein kinase C and 
protein k:i.nase A 128 . Whereas the ca2+ dependen~ protein kinase C activates 
tyrosi~•e kinase. 
increased ca2+ 
the cAMP dependent protein kinase A inhibits it. 
mobilisation activates phospholipase A2 directly 
Thus. 
and by 
s~imulating protein kinase C activi~y. hence stimulating lipocortin 
phosphorylation, it prevents the inhibi~ion of phospholipase A2 . cAMP has 
opposite effects: by stimulating Na+jca2+ exchange it lowers the intracellular 
Ca2+ concentration67 . Furthermore it activates protein kinase A which results 
1n an increased availability of lipocortin. 
Prostaglandins and thromboxane 
Free arachidonic acid can be converted by two main pathways (cyclooxygenase 
and lipoy~genase) to a variety of biologic~:ly h~ghly-active compounds. The 
cyclooxygenase pathway (figure 2) directly generates prostaglandin (PG) c2 from 
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arachidonic acid by the action of an enzyme that is inhibited irreversibly by 
aspirin and non-competitively reversibly by other non-steroidal 
anti-inflammatory compounds. The enzyme has been termed cycle-oxygenase or PC 
endoperoxide synthetase and its mode of action has been proposed to be an 
initial lipoxygenase type of reaction with introduction of oxygen at c 11 . 
Further oxygenation and cyclization yields PCc2 . an unstable endoperoxide. which 
is reduced in a hydroperoxidase reaction to PCH2 . PCH2 is then subject to 
parallel enzymatically c~talyzed reactions to yield s~x products. These 
products include four prostaglandins PCD2 • PGE2 • PGF2~ and PGI2 (prostacyclin), 
219 a 17-carbon cleavage product (HHT) and thromboxane A2 . Each prostaglandin is 
designated by a letter. indicating the nature of the cyclopentane substituents 
a~d by a subscript which indicates the number of double bonds, being dependent 
upon the precursor fatty acid. Whereas archidonic acid gives rise to the 
prostaglandins of the dienoic dihomo-Y-linoleic acid and 
eicosapentaenoic acid are converted into PC1 and PC3 groups of compounds 
reepectively. 
Leukotrienes 
In addition to the products of the cyclooxygcnase pathway, a number of 
non-cyclized compounds have been described as metabolites of arachidonic ac1d 
via lipoxygenase pathways that are not inhibited by the non-steroidal 
anti-infl~atory drugs to the same extent. These pathways include the 5-, 12-
and 15-lipoxygenase routes of which the 5-lipoxygenase pathway g~vcs ri::;c to 
leukotricnes97 . Arachidonic acid is oxidatively metabolized v1a the 
5-lipoxygenase to 5-hydroxypcroxyeicosatetraenoic acid (5-HPETE) and then e1ther 
to the related monohydroxyeicosatetraenoic acid (5-HETE) or to an epoxide 
intermediate known as lcukotriene A4 (LTA4 ). LTA4 ca~ be converted by two 
enzymatic routes to other leukotrienes or by non-enzymatic hydrolysis to 5,12-
and 5.6-di-HETE's (figure 3). The first enzym~tic rou~c of metabolism of LTA4 
involves opening of the epoxide with glutathione as a nuclcophilc 182 to produce 
the peptidolipid conjugate LTC4 . LTC4 is sequentially metabolized to LTD4 by 
removal of 
cleavaee of 
a glutamic 
glycine 161 . 
acid residue from the peptide 179 and then to LTE4 by 
These three leukotrienes collectively account foe the 
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biological activity knovn as slow-reacting substance of anaphylaxis (SRS-A). 
The second enzymatic route involves the hydration of LTA4 to produce a 
5,12-di-HETE, termed LTB4 , and was first described in 
leukocytes33 . 
Lipoxins 
polymorphonuclear 
In 1984 Serhan. Hamberg and Samuelsson announced the isolation of a new 
class of metabolites of arachidonic acid, the trihydroxyeicosatetraenoic acids 
or lipoxins234 . The name lipoxin is in recognition of their being presumptive 
lipoxygenase products. In contrast with leukotrienes however, lipoxins are not 
derived via the 5-lipoxygenasc but via the 15-lipoxygenase pathway. Arachidonic 
acid is oxidatively metabolized via this enzymatic route 
15-hydroperoxyeicosatetraenoic acid (15-HPETE). A second oxidation at c 5 yields 
5,15-di-HPETE, which can undergo enzymatic dehydration to produce a 5.6 epoxide. 
Enzymatic hydrolysis of the epoxide at c 6 would lead to lipoxin A (LXA), while 
addition of water at c 14 would produce LXB. However, in a recent publication
5 
the in vitro synthesis of LXA and LXB was described whereby a.o. leukotricne A4 
was used as starting material. Therefore, the exact in vivo metabolism of 
lipoxins still remains to be solved. 
3 FUNCTION 
Eicosanoids arc involved :n numerous physiological or pathophysiological 
processes. These processes include neurotransmission. hormonal interactions and 
effectivity, reproductive physiology. labour and childbirth, gastrointestinal 
physiology, pulmonary physiology, renal physiology and diuresis, cardiovascular 
physiology and blood clotting and also inflammation and immunornodula":;ion. 
Considering the scope of this thesis only the effects of eicosanoids on 
inflammation and the immune system will be discussed. 
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Prostaglandins 
The experimental evidence which supports the view that prostaglandins 
influence 
reactions 
tho 
is 
development and modulation of 
voluminous26.100,105,157,250. 
immune processes and inflammatory 
Among these prostaglandins. 
prostaglandin E2 • predominantly synthesized by macrophages
100
• has gained a 
certain prominence as it has been shown to affect more than other cyclooxygenase 
products both inflammatory ~~d immune responses28 Prostaglandin E2 appears to 
exhibit two seemingly confusing effects, namely pro- and ~~ti-inflammatory 
actions. Some of this confusion is avoided when one considers effects of 
prostaglandins on vascular or -acute- components of inflammation seperately from 
their effects on tissue components. The classical symptoms of inflammation 
namely redness (vasodilatation), svelling (increased capillary permeability) and 
pain (sensibilisation of neurones to bradykinin or histamine) which are all due 
to the action of prostaglandin E2 . are characterized by a rapid and early 
occurence during inflammation and they can impressively be inhibited by the 
non-steroidal anti-inflammatory drugs. However. as has been shown in the 
carrageenan induced granuloma model27 , in a later stage of infl~~ation 
prostaglandin E2 exhibits anti-inflammatory properties. The anti-inflammatory 
and immunomodulatory effects of prostaglandin E2 are most likely due to its 
capacity to stimulate the adenylate cyclase activity of a variety of cells 
including fibroblasts, lymphocytes, macrophages, eosinophils and neutrophils29 
An increase in cyclic AMP predominantly represents an inhibitory signal ~or 
various functions. although some exceptions have been noted. Thus it is known 
that prostaglandin E2 reduces a.o. fibroblast proliferation and collagen 
synthesis. lymphocyte proliferation, killing by cytolytic T cells. natural 
killer cell activity and lymphokine production by macrophages250 . On the other 
h~~d. prostaglandin E2 induces collagenase production by macrophages 257 . Also 
it appears that maturation of thymocytes is enh~~ccd by cyclic AMP generating 
hormones such as prostaglandin E2
105
. More information is definitively required 
to elucidate the role of prostaglandin E2 as an immune/inflammatory regulator 
molecule with either ouppressive or stimulating properties. 
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Leukotrienes 
The rationale ~or seeking pharmacotherapeutic agents to limit leukotriene 
biosynthesis and/or end organ effects is based upon: 1- the demonstrated in 
vitro capacities of certain cells and tissues to generate leukotrienes in 
response to selected agonists, 2- the potent pro-in~lammatory actions o~ these 
compounds in pharmacological studies {table 1) , 3- the recovery and measurement 
of leukotrienes in biological fluids associated with certain disease states 
(table 2) and 4- the knowledge that non-steroidal anti-inflammatory drugs have 
substa~cial c~ficacy, but modi~y only one o~ the two major routes of arachidonic 
acid metabolism. 
Among the cells relevant to an inflammatory response the production of 
leukotrienes seems to exhibit a remarkable cellular speci~icity. Whereas 
polymorphonuclear leukocytes generate leukotriene B4 in a 10-fold 
with eosinophils262 . 
excess 
relative to leukotriene c 4 , this ratio is reversed 
peripheral blood monocytes release both leukotriene B4 
Hum= 
and leukotriene c4266 and 
human alveolar macrophages are reported to respond to stimulation with the 
Ca-ionophore A23187 with a preferenti-al leukotriene B4 generatJ.on
87 However 
some caution has to be taken with respect to the interpretation of these data. 
Thus it is shown that stimulation of human alveolar macrophages with arachidonic 
acid resulted in the production of leukotriene D4
64
• whereas huma~ peritoneal 
macrophages responded to A23187 with a release of both leukotriene B4 and 
leukotriene c 4
74
. Therefore depending on the site in the inflammatory focus. 
~he cell type involved a~d the stimulus applied. the leukotriene production ca~ 
predominantly be leukotriene B4 or leukotrienes c 4;D4 with distinct biological 
activities. 
A number of biological activities have been described foe tho 
5-lipoxygenase products. Leukotriene B4 has been shown to be one of the most 
powerful agents that stimulate chemokinesis of leukocytes and to act as a 
chemotactic compound with a potency comparable to other important chemotactic 
agen~s such as the complemen~-derived peptide C5a and the synthetic peptide 
formylmethionylleucylpher.ylalanine. In addition, leukotriene B4 seems to 
augment leukocyte activ:ty as could be observed with respect to aggregation, 
superoxide production, lysosomal enzyme release, gl~cose metabolism and 
expression of C3b receptor sites. In vivo studies showed that leukotriene E4 
mediated inflammato~y reactions by recruiting leukocytes. by mediating vascular 
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Table 1. Biological effects, induced by 5-lipoxygenase products. 
in vitro effects 
target 
PMN/eo/M//Mo 
PMN/eo 
PMN 
PMN 
M/ 
T lymphocyte 
NK cell 
metabolite 
5-HETE 
LTB4 
lung parenchymal tissue LTc4;n4 
in vivo effects 
effect 
chemokinesis 
chemotaxis 
C3b receptor site eXpression 
reference 
36,94.237 
195 
184 
complement dependent cytotoxic reaction 178 
adherence 
ca2+ and Na+ influx 
intracellular cAMP level 
superoxide production 
lysosomal enzyme release 
adherence 
chemiluminescence 
95 
177 
48 
233 
204 
104 
121 
release of cyclooxygenase metabolites 89 
Ia antigen production 
T suppressor cell induction 
natural cytotoxic cell activity 
contraction 
TxA2 release 
leukocyte accumulation 
increased vascular permeability 
hyperalgesia 
vasodilatation 
increased vascular permeability 
stimulation of mucus production 
bronchoconstriction 
240 
208 
209 
9 
273 
34 
35 
203 
19 
96 
141 
260 
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Table 2. Involvemen~ of 5-lipoxygenase produc~s in pathological condi~ions 
Disease me~aboli~e reference 
asthma LTC4 62 
psoriasis LTB4;c4 72,113 
gout LTB4 205 
rheuma~oid arthri~is LTB4 205 
ulcera~ive colitis LTB4 235 
pleurisy LTC4 JD4 249 
permeability changes and by modulating pain responses. Furthermore. suppression 
of human T lymphocy~e function, possibly ~hrough induc~ion of huma~ suppressor 
T lymphocy~cs. and ac~iva~ion of natural cy~otoxic cells are aspects of the 
immunomodulatory role of leukotricne B4 . 
Already before the leuko~riene s~ructurcs vere elucidated, slav reac~ing 
subs~ance of anaphylaxis (SRS-A) vas known ~o be a cons~ric~or of human airway 
~mooth muscle37 . More recen~ly, these effec~s of SRS-A have been confirmed and 
ex~ended vith syn~hctic leukotriene c 4 and leukotriene D4 bo~h in vivo and in 
vitro. Other interesting features in the action of the peptido-leukotrienes on 
the l~~g are their ability to stimulate mucus production and to induce vascular 
permeability changes. Contraction. mucus production and edema are major aspects 
of asthma and indeed it has been shown that antigen challenge of human asthmatic 
lung leads to the release of peptido-leukotrlencc 62 These findings and the 
fact that macrophages from asthmatic individuals synthesize more leukotriene D4 
hypothesis that than macrophages from normal subjects64 lead to the 
peptido-leukotricnes are maJOr mediators involved in human allergic asthma. In 
addition these leukotrienes have other properties that could be important in 
terms of mediation of inflarwnatory reactions. They are potent vasodilators, 
enhance neutrophil adherence a~d modulate the release of mediators from 
macrophages which is the subject of this thesis. 
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Lipoxins 
Since the structure of lipoxin A and lipoxin B has only been elucidated 
very recently, the relevance of lipoxins on inflammatory or immune processes 
still is open to question. Of potential interest are the biological actions of 
these lipoxins, vhich involve: regulation of natural killer cell activity, 
stimulation of superoxide and lysosomal enzyme release from polymorphonuclear 
leukocytes and contraction of the guinea pig lung parenchymal strip221 
Hovever. whereas Samuelsson reported that both lipoxin A and lipoxin B inhibited 
natural killer cell activity221 a recent paper shoved that lipoxin A in lev 
concentrations actually enhanced vhereas higher concentrations inhibited this 
activity160 It is evident that the availability of synthetic lipoxins, as vas 
recently reported5 , will go far tovards the elucidation of the relev~~ce of 
lipoxins in pathophysiological processes. 
This short review of effects of eicosanoids should emphasize one important 
aspect. Metabolism of arachidonic acid yields a variety of mediators vhich 
differ tremendously in their respective activity. A complicated, but bal~~ced 
netvork of interactions appears to evolve that may markedly influence 
inflammation or imm~~oregu~ation at an unspecific level. It probably vill turn 
out that this immunologically ~~specific system is intricately involved in the 
regulation of the more sophisticated and immunologically specific networks of 
the immune response. 
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CHAPTER 3. ADENYLATE CYCLASE 
1 INTRODUCTION 
Mili~y hormonally responsive sys~ems arc regula~ed ~hrough ch~~ses in 
in~racellular cylic nucleo~ide levels, and it is well 
hormones-such as pro~taglandins30 •79 ~~d macrophages respond ~o 
~-adrenergic agents 115 · 263 by an increased production 
documen~cd tha~ 
drugs such as 
of 3'5'-cyclic 
adenosylmonophosphatc (cyclic AMP)- Increased levels of this nucleotide are 
known to modify cell metabolism and to influence such parameters as reactive 
oxygen production164 . lysosomal enzyme release 169 • prostaglandin production163 , 
aggregation216 , phagocytosis268 cytotoxici~y228 and Ia antigen expression240 
To better understand how such macrophage functions are regulated. it is 
important to describe the underlying mechanisms of cAMP produc~ion and the 
proposed mechanism of action. 
2 METABOLISM 
Currently, activation of adenylate cyclase by hormones is considered to 
involve a ternary complex. This complex consists of: 1- a discriminator, a 
hormone specific receptor, 2- a transducer, transmitting the signal from the 
receptor to ~he effector system and 3- an amplifier, which is formed of the 
effector system (adenylate cyclase) 207 . Studies whereby adenylate cyclase 
deficient membranes were reconsti~uted with extracts from cell membr~~es of 
norm~l cells demonstrated that the transducer consists of a regulatory protein, 
which is guanosyltriphosphate (CTP) dependent214 ~he c 8 or guanine nucleotide 
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regulatory protein. Furthermore it vas shovn that thv rate limiting step ln ~he 
process that leads to enha~ced cyclic AMP formation is a change at the level cf 
the Gs protein47 . Gs protein contains two types of subunits, ~and e. whereby 
the a subunits have been assessed to bind GTP 188 . Since it appeared that Gs 
protein activation is dependent on Mg2 +139 and is followed by a reduction in its 
size 120 , it has been postulated that Gs activation by GTP and Mg2 + is associated 
with a subunit dissociation event followed by combination of the GTP-loaded 
a subunit wi~h the catalytic unit of adenylate cyclase236 (figure 1 ). 
Although many hormones act by increasing cellular levels of cyclic AMP. it 
is also well known that application of certain hormones lowers this level. 
Among these are a 2-adrenergic agonists, muscarinic agonists and opiates
140 As 
was the case with stimulation, also with hormonal inhibition the presence of a 
guanine nucleotide regulatory protein, Gi' could be demonstrated126 . Although 
the subunits of Gi are different from those of G8 • the general build-up of the 
protein is comparable to G8 with one difference: the inactive form of c 1 
activation 5 1 contains GDP bound to the a-subunit which is exchanged for GTP upon 
(figure 1). 
3 FUNCTION 
Although the exact mode of action by which cyclic AMP modulates cellular 
activity is not knovn yet. two mechanisms are known by which cyclic AMP affects 
cellular metabolism: protein phosphorylation53 and interference with a second 
intracellular 
phosphorylase 
messenger, 
kinasc267 , it 
calcium17 . Originally discovered as an activator of 
soon became evident that the cyclic AMP dependent 
proteine kinase A must have a much wider role in mediating the effects of cyclic 
AMP as it was known that cyclic AMP affects other processes than glycogenolysis 
(table 1). The specificitY of the response is determined by the presence of 
different substrate enzymes in different cells. With respect to arachidonate 
metabolism. one of the substrates for proteine kinase A is tyrosine kinase. As 
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vas described in chapter 2. part 2 inactivation of tyrosine kinase by protein 
kinase A will lead to a decreased metabolism of arachidonic acid. These effects 
are counteracted by intracellular calcium vhich activates tyrosine kinase. 
Next to the interaction between cyclic AMP and calcium described above, 
cyclic AMP is knovn to modulate the intracellular calcium concentration by two 
distinct mechanisms. Firstly, it has been shovn that cyclic AMP stimulated 
Na+jca2 + exchange, thus lowering the intracellular calcium concentrations67 . 
Secondly, cyclic AMP causes the phosphorylation of the protein phospholamban. 
resulting in an increased uptake of calcium by the sarcoplasmic reticulum and 
therewith a reduced availability of calcium154 • Whereas these mechanisms both 
result in a decreased concentration of calcium, one major interaction between 
cyclic AMP and calcium results in an increased effectivity of the latter. 
Phosphorylase kinase A not only is a target for cyclic AMP dependent proteine 
kinase A but is also dependent on calcium122 . Phosphorylation of this enzyme 
Table 1. Protein kinase affected enzymes (modified after Cohen,1982). 
activated 
calmodulin 
phosphorylase kinase 
triglyceride lipase 
cholesterol esterase 
fructose 1-6 biphosphatase 
phenylalanine hydroxylase 
tyrosine hydroxylase 
phospholamban 
inhibited 
glycogen synthase 
glycerol phosphate acyl transferase 
acetyl Co-A carboxylase 
6-phosphofructo 2-kinase 
pyruvate kinase 
tyrosine kinase 
myosin light chain kinase 
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by protein kinase A allowed activation by calcium to occur at lower 
concentrations52 . Phosphorylase kinase has a subunit structure. whereby one of 
the subunits was ~ound to be identical to calmodulin259 . It has recently become 
clear that many of the biological actions of calcium are regulated by calmodulin 
in a manner that closely resembles the actions of cyclic AMP as a regulator of 
enzyme Whereas cyclic AMP stimulates the activation of 
calmodulin, calmodulin stimulates both adenylate cyclase and phosphodiesterase. 
the enzymes involved in the metabolism and breakdown of cyclic AMP 103. In 
conclusion, it becomes increasingly apparent that cellular processes are 
controlled by an intricate network of intracellular signals of which the cyclic 
nucleotides and calcium are key components. 
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CRAFTER 4. RELEASE OF EICOSANOIDS FROM MACROPRAGES 
1 INTRODUCTION 
Of all the leukocytes macrophages regularly impress as the most efficient 
eicosanoid producers 101 They are 
lipoxygenase-derived products206 •239_ 
known to release both cyclooxygenase- and 
Several investigators have shown a 
concomitant activation of the cyclooxygenase and lipoxygenase pathways. 
following 
A2318?74 , 
exposure of macrophages 
zymosan217 and immune 
in vitro to different stimuli as ionophore 
complexes231 . However, it has been shown that 
soluble, membrane mediated inflammatory stimuli such as phorbol myristate 
acetate and lipopolysaccharide stimulated the cyclooxygenase pathway without 
affecting lipoxygenase activity137 . On the other hand a recent paper describes 
the converse. It was shown that Y-hexachlorocyclohexane stimulated the 
formation of lipoxygenase products, having only a minor effect on prostaglandin 
production170 . The results of these two groups could be explained by the 
existence of two different, independent sources of substrate arachidonic acid, 
as has been suggested previously132 . The implication of this concept would be 
that prostaglandin and leukotriene production are independently mediated. 
However, one should bear in mind that comparing eicosanoid release from 
cells using different stimuli can be quite confusing. Properties of macrophages 
vary according to their ~state of activation~. As discussed in chapter 1, 
part 3 the typical. activated macrophage does not exist 183 . Nevertheless some 
general alterations appear to be valid for all situations. Whereas in vitro 
stimulation of macrophages leads to enhanced eicosanoid ~elease, activated 
macrophages, elicited in vivo with different inflammatory stimuli, have a 
reduced capacity 
lipoxygenase-derived 
to convert arachidonic acid to 
products 136 •23°. Another well-known 
cyclooxygenase- and 
aspect of activated 
macrophages is their ability to release substantial amounts of lysosomal 
hydrolases65. This secretion generally is considered to be an aspecific but 
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Figure 1. Basal secre~ory levels of 
resident peritoneal macrophages (RES). 
carrageenan (2 mg i.p.) elicited macro-
phages (CAR) and Freund's incomple~e ad-
juvan~ (2 ml i.p.) elicited cells (FIA). 
Prostaglandin E2 (PCE2 , open bars), 
thromboxane B2 (TxB2 , hatched bars) and 
$-glucuronidase (CUR, dotted bars) vere 
measured. An inverse relation between 
the production of the cyclooxygenase me-
tabolites PGE2 and TxB2 and the release 
of the lysosomal enzyme $-glucuronidase 
could be observed. 2.5x10 6 cells were 
incubated during 1.5 hat 37°C in a hu-
midified atmosphere containing 5~ C0 2 in 
air. Means± SEM (n~5). 
Figure 2. Basal secretory release of 
leuk:otriene c 4 (LTC4 , open bars) and 
f.-glucuronidase (CUR, dotted bars) from 
resident (RES) and carrageenan (CAR) or 
Freund's incomplete adjuvant (FIA) eli-
cited peritoneal macrophages. Note the 
positive relation betveen LTC4 and CUR 
release. 10x106 cells/10
0
ml were incuba-
ted for 15 minutes at 37 C in the pre-
sence of gluthatione (2 mM), arachidonic 
acid ( 10 •&) and serine (0.25 mM). 
Means ± SEM (n:=4). 
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important indicator of cell activity225. 
With the experiments described in the following sections of this chapter an 
attempt was made to correlate eicosanoid release with macrophage activity, for 
which lysosomal enzyme release was taken as a criterion. 
2 INDEPENDENT REGULATION OF CYCLOOXYGENASE 
AND LIPOXYCENASE ACTIVITY 
Three different populations of rat peritoneal macrophages were obt~ined by 
peritoneal lavage; resident cells without prior intraperitoneal stimulation and 
elicited cells on the fourth day after an intraperitoneal injection of 
carrageenan or Freund's incomplete adjuvant (vide Appendix. Materials and 
Methods for a detailed description of the experimental conditions). As can be 
seen in figure 1 an inverse relation could be observed between the release of 
the lysosomal enzyme ~-glucuronidase and the production of the cyclooxygenase 
products prostaglandin E2 
Whilst enzyme activity (i.e. 
a~d thromboxane A2 , 
cell activity) was 
measured as thromboxane B2 . 
more pronounced in elicited 
macrophages. the reverse was observed with prostaglandin E2 and thromboxane A2 . 
Leukotriene release on the other hand was found to be positively correlated with 
enzyme release {figure 2). No detectable levels of leukotriene c 4 were measured 
in the supernatant of resident cells, whereas carrageenan and Freund's 
incomplete adjuvant elicited macrophages released 3.85 and 4.55 pmoles 
leukotriene c 4 respectively. 
It has been suggested 
Leukotriene B4 , D4 or E4 could not be detected. 
that a decreased availability of substrate 
arachidonic acid is the factor responsible for the reduced capacity of elicited 
macrophages to secrete eicosanoids231 • due, for example, to a decrease in the 
activity of phosphol~pase A278 However. the results obtained in the present 
eA~eriments are in contradiction with these findings. Whereas the release of 
cyclooxygenase-derived products indeed was decreased. leukotriene c 4 release was 
enhanced. A possible explanation for this difference could be the postulated 
~ increase 
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Figure 3. E~~ec~s o~ arachidonic acid (AA) on ~he production o~ prostaglandin E2 
(PGE2 , 0) and thromboxane B2 (TxB2 , •) ~rom carrageenan elicited macrophage& 
(panel A1) or Freund's incomplete adjuvant elicited macrophages (panel A2). 
TxB2 production was saturated at much lo~er concentrations o~ AA than was PGE2 
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existence of at least two phospholipase A2 pools in macrophages
265
. Since 
5-lipoxygenase, the initial enzyme in the lipoxygenase pathway, is a soluble 
enzyme and thus presumably resides in the cytosol, whereas cyclooxygcnase is 
membrane bound, it is very likely that these enzymes use arachidonic acid from 
different phospholipid sources210 These findings add further support to the 
hypothesis that prostagla~din and leukotriene synthesis are independently 
regulated. 
3 PREfERENtiAL PROS!AGLANDIN E2SYNTHESIS IN RESPONSE 
TO ARACEIDONIC ACID STIMULATION 
As could be seen in figure 1, elicited macrophages have a reduced capacity 
to produce cyclooxygenase products. In addition to this decreased activity. 
also a shift within cyclooxygenase activity could also be observed. Vhereas 
resident macrophages produced as much prostaglandin E2 as thromboxane A2 . 
elicited macrophages produced less. In general the lower the production of 
prostaglandin E2 , the more active the cell, as measured by lysosomal enzyme 
release, and the greater, relative to prostaglandin E2 . the formation of 
thromboxane A2 . However, exposing the macrophages to the precursor arachidonic 
acid completely reversed this situation. As can be seen in figure 3, panel A, a 
dose dependent increase of prostaglandin E2 production could be observed in the 
presence of archidonic acid, whereas thromboxane A2 production was saturated at 
production. Panel B: ratio between PGE2 and TxB2 as was found with carrageenan 
(0) or with Freund's incomplete adjuvant ( o) elicited cells. Panel c: 
production of PGE2 (open symbols) and TxB2 (closed symbols) by Fre~~d's 
incomplete adjuvant elicited cells; macrophages were incubated with a cell 
number of 2. 5x ( 0), 5X ( 0) or 1 Ox1 o6 (.A) cells/ml. Note that the production 
of both metabolites was independent on the 
conditions as described in the legend to figure 1. 
(Student's t-test, two-tailed). 
number of cells. Experimental 
Means ± SEM, n~5. * P<0.01 
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lov concentrations of the fatty acid. Furthermore, calculating the ratio 
betveen the tvo cyclooxygenase products after exposure to archidonate indicated 
that prostaglandin E2 vas the major metabolite (figure 3, panel B). Some slight 
differences vere observed betveen the tvo populations of elicited macrophages 
vhich vere used in this study. Firstly, in carrageenan elicited macrophages 
(figure 3. panel A1) prostaglandin E2 production could not be saturated, in 
Freund's incomplete adjuvant elicited cells it could (figure 3. panel A2). 
Secondly, vhereaz thromboxane A2 production in carrageenan elicited macrophages 
vas maximal vith 1 pg arachidonic acid and could not be increased further, in 
Freund's incomplete adjuvant elicited cells thromboxane Az release actually 
decreased. Thirdly, the shift from thromboxane A2 to prostaglandin E2 vas more 
pronounced in Freund's incomplete adjuvant elicited macrophages. These data 
vere extended by recent observations in our laboratory, shoving that resident 
macrophages responded to arachidonic acid in a comparable vay82 . Both 
prostagl~~din E2 and thromboxane B2 vere increased vhereby thromboxane A2 
release vas saturated vith 5 pg arachidonate. Hovever, the amounts of 
prostaglandin E2 released never exceeded those of thromboxane B2 . 
In conclusion. these results indicate that during in vivo activation 
cyclooxygenase activity is changed, vhereby prostaglandin E2 formation is 
preferentially inhibited. The more active the cell, the lover the production of 
prostaglandin E2 . both abolute and relative to other cyclooxygenase metabolites. 
Restoring the decreased availability of substrate by exposing the cells in vitro 
to arachidonic acid yields the converse pattern. Both elicited and resident 
macrophages react with a preferential increase of prostaglandin E2 formation. 
Interestingly this increase was found to be more pronounced in active 
macrophages, indicating that prostaglandin E2 is the major cyclooxygenase 
metabolite upon activation of these cells. As will be discussed later in this 
thesis prostaglandin E2 plays a dominant role in the regulation of macrophage 
functions. 
An interesting aspect of archidonate induced prostaglandin release vas 
observed vith cell suspensions containing different cell numbers. In contrast 
to vhat was expected, the production of cyclooxygenase metabolites vas 
completely independent of the number of macrophages present in the suspension. 
In figure 3. panel G a graphical presentation is offered of the results obtained 
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with Freund's incomplete adjuvant elicited macrophages. Although absolute 
values differed (Freund's incomplete adjuvant elicited cells consistently 
produced significantly less cyclooxygenase metabolites) similar cha~ges were 
observed with carrageenan elicited macrophages (data not shown). Evidently the 
amount of the metabolites produced was dependent on two factors: 1- the 
concentration of the precursor fatty acid and 2- the concentration of the 
metabolite produced. At a given concentration of 5 ~& arachidonic acid/ml. 2.5. 
5 a~d 10.10 6 cells/ml all released prostaglandin E2 up to a final concentration 
of ± 3 pmoles/ml a~d thromboxane to a concentration of± 2.5 ~molesjml. These 
values were found to be dependent on cell activity, since the less active 
carrageenan elicited macrophages released substa~tially more (± 11 pmoles/ml and 
± 9 pmoles/ml respectively). 
It is known that elicited macrophages display. in terms of adenylatc 
cyclase stimulation and subsequent rise of cyclic AMP, a high responsiveness to 
prostaglandin E2 . Resident cells with a~ optimally functioning cyclooxygenase 
system were rather unresponsive30 . It was also reported that the reduced 
capacity of the cyclooxygenase pathway in elicited macrophages was accompa~ied 
by low intracellular cyclic AMP levels78 . Furthermore it has been shown that 
prostaglandin E2 inhibited the release of other cyclooxygenase metabolites from 
elicited macrophages80 In view of these facts and because prostaglandin E2 is 
the major cyclooxygenase metabolite of elicited macrophages, it is possible 
that, via activation of adcnylate cyclase, prostaglandin E2 was responsible for 
the effects described in the previous paragraph. 
The results discussed in the previous paragraph were obtained with rat 
peritoneal macrophages. It should be noted that although prostaglandin E2 is 
the major cyclooxygenase metabolite in rat macrophages, due to species 
differences this finding cannot be extrapolated to human cells. In fact. 
previous investigations in our laboratory revealed that human peritoneal 
macrophages are more sensitive to prostacyclin than to prostaglandin E2
30 
These macrophages had been collected from the dialysis fluid of renal patients 
on continuous ambulatory dialysis at a time when no complications were present. 
However. during an intercurrent infectious peritoneal inflammation the cells 
displayed a marked increase in reactivity towards prostaglandin stimulation with 
was more pronounced with prostaglandin E2
7 The original difference30 between 
the responsiveness of the cells to the prostaglandins was abolished. Whereas 
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Figure 4. Release of leuko~riene c 4 (LTC4 , panel A) or leuko~riene B4 (LTB4 , 
panel B) from resident (.6.), carrageenan elici~ed (e) or Freund's incomplete 
adjuvan~ elicited ( 11) macropha.ges af'ter exposure of the cells to the 
Ca-ionophore A23187. Although the basal leukotriene production was enhanced in 
elici~ed 
A23187. 
measured 
in the 
tailed). 
macrophages, resident cells responded far better to stimulation with 
In all cell populations leukotriene B4 production could only be 
in the presence of the ionophore. Experimental procedure as described 
legend to figure 2. Means± SEM (n~4), • P<0.01 (Student's t-test, two 
- 47 -
these results indicate that also in human cells during inflammation 
prostaglandin E2 is a ffiajor cyclooxygenase metabolite, the reason for the 
discrepancy betveen the responsiveness of inflammatory versus non-inflammatory 
cells to the different prostaglandins remains puzzling. 
4 LEUKOTRIENE c4 IS THE MAJOR LIPOXYGENASE METABOLITE AFTER IN VIVO 
STMULATION. LEUKOTRIENE B4 AFTER IN VITRO STIMULATION 
Figure 4 depicts the release of leukotriene c 4 (panel A) and leukotriene B4 
(panel B) after stimulation of the. three cell populations studied vith the 
Ca-ionophore A23187. In general, all populations responded to the ionophore 
vith an enhanced release of both leukotriene c 4 and leukotriene B4 . More 
specifically several points are of interest. Resident macrophages do not 
produce leukotriene c 4 unless stimulated with 10-
6 M A23187. Elicited 
macrophages did release leukotriene c 4 under basal conditions whereby a positive 
correlation with cell activity was established. Hovever. compared with resident 
macrophages these cells responded poorly to stimulation. Increases, due to 
A23187, were only significant at 10- 6 M ionophore. and in this respect these 
cells resembled resident macrophages. but at this concentration of ionophore 
resident cells released about four times as much leukotriene c 4 . Although 
leukotriene B4 was not produced under basal conditions, this leukotriene is 
evidently the major metabolite after stimulation. Leukotriene B4 levels in the 
presence of 10- 6 M A23187 exceeded those of leukotriene c 4 4.4-10.6 fold. Again 
elicited macrophages showed a reduced capacity to secrete leukotriene B4 as 
compared to resident cells. 
The conclusions which can be drawn from these experiments are twofold: 1-
leukotriene B4 is the major lipoxygenase metabolite released from macrophages 
and 2- as with cyclooxygenase activity, the lipoxygenase pathway appears to be 
depressed in elicited cells. Although these conclusions seem evident, caution 
must be taken for the following reasons. Most other workers. who measured 
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macrophage leukotriene production, used mouse or human cells. These works 
reported a 
to the 
concomittant release 
Ca-ionophore74 • 193 . 
of leukotriene B4 
When different 
and leukotriene c4 in response 
stimuli were used, e.g. 
y-hexachlorocyclohexane or IgE, a preferential synthesis of leukotriene c 4 and 
leukotriene B4 respectively was observed
170
•
2 66. Again, the existence of 
different arachidonic acid pools might offer a valid explanation for these 
variations. As yet, the simultaneous release of leukotriene c 4 and 
leukotriene B4 from resident rat peritoneal macrophages has not been reported. 
Earlier studies showed that resident rat macrophages released leukotriene B4 , 
whereas elicited cells released leukotriene c4 , both in response to ionophore 
stimulation10 · 70 . More recently the release of leukotriene c4 from resident 
peritoneal macrophages was reported206 . However. in this study the cells were 
harvested after an intraperitoneal lavage with saline. As was shown in our 
laboratory 
the Na+/K+ 
saline instantly activates macrophages, possibly via modification of 
ATPase81 . A second study from our laboratory reported that saline 
elicited macrophages responded to A23187 stimulation with the release of both 
peptidoleukotrienes and leukotriene B4
267 Neither in human. mouse nor in rat 
macrophages basal release of leukotrienes has been studied. The present study 
establishes, for the first time, basal leukotriene c 4 release. Furthermore 
these levels were positively correlated with cell activity, indicating that 
leukotriene c4 is the major lipoxygenase metabolite produced after in vivo 
stimulation. In the light of other results, discussed in different parts of 
this thesis, the enhanced basal release of leukotriene c 4 from elicited 
macrophages is of particular interest. As will be discussed in chapter 5 this 
peptidoleukotriene is considered to be an important mediator in cellular 
activation. 
The general reduction in lipoxygenase activity observed in elicited 
macrophages, is possibly due to an effect of A23187 on cyclic AMP. It has been 
shown that elicited rat peritoneal macrophages respond to A23187 with an 
increase of the intracellular cylic AMP level, which was prostaglandin 
mediated162 . Taken together with the high responsiveness of elicited 
macrophages to prostaglandin E2
30
, this interaction may represent a mechanism by 
which macrophage activity. in terms of of lipoxygenase metabolite production is 
regulated. 
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5 SUMMARY AND CONCLUSIONS 
The respective capacities of rat peritoneal macrophages to metabolise 
arachidonic acid into prostaglandins and leukotrienes vere compared. For this 
purpose three different cell populations vere used, resident cells and 
carrageenan or Freund's incomplete adjuvant elicited macrophages. An inverse 
relation betveen lysosomal enzyme release. a non-specific indicator of cell 
activity, and cyclooxygenase derived products could be observed. Whereas 
Freund's incomplete adjuvant elicited cells released more $-glucuronidase than 
carrageenan elicited ~~d resident cells, the reverse vas observed vith respect 
to prostaglandin E2 and thromboxane A2 production. Furthermore, it vas shovn 
that upon in vivo activation prostaglandin E2 vas preferentially inhibited. On 
the other hand. resident cells did not release leukotriene c 4 but elicited 
macrophages did. Thus leukotriene c 4 release vas positively correlated to cell 
activity, being indicative of an important role of leukotriene c 4 in cell 
activation. In conclusion: in vivo activation of macrophages is accompanied by 
increased lysosomal enzyme and leukotriene c 4 release and decreased production 
of cyclooxygenase metabolites, whereby prostaglandin E2 is preferentially 
inhibited. 
Restoration of the decreased precursor availability by exposing elicited 
macrophages to various concentrations of arachidonic acid resulted in an 
increased release of cyclooxygenase metabolites. Varying the number of cells in 
the suspension had no effect on the maximal release. Apparently prostaglandins 
were produced up to a fixed concentration, vhich vas found to be dependent on 
cell activity. The less active carrageenan elicited macrophages produced three 
times as much cyclooxygenase metabolites compared vith the more active Freund's 
incomplete adjuvant elicited cells. Furthermore, exposure of the cells to 
arachidonate resulted in a preferential synthesis of prostaglandin E2 , vhich was 
more pronounced in the more active cells. In conclusion: in vitro stimulation 
of macrophages with arachidonic acid leads to a preferential production of 
prostaglandin E2 to a fixed maximal concentration which is dependent on cell 
activity. 
Finally, it was shown that elicited macrophages, despite high basal 
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secre~ory levels of leukotriene c4 , have a reduced lipoxygenase activity. 
Compared to residen~ macrophages these cells poorly responded 'O '"e 
Ca-ionophore A23187. The amount of leukotriene c4 produced by resident 
macrophages upon maximal stimulation was at least 3.5 times as much as that 
produced by elicited cells. Furthermore, in response to A23187 leukotriene B4 
was the lipoxygenase metabolite which was predominantly produced, both in 
resident and elicited cells. No leukotriene D4 or leukotriene E4 could be 
detected. In conclusion: in vitro stimulation of macrophages with A23187 leads 
to production of 
major metabolite; 
leukotriene B4 
despite high 
and leukotriene c4 • leukotriene B4 being the 
basal leukotriene c4 production elicited 
macrophages have a reduced lipoxygenase activity. 
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CHAPTER 5. EFFECTS OF EICOSANOID$ ON MACROPHAGE FUNCTIONS. 
1 INTRODUCTION 
Macrophages are not only a source of eicosanoids, but also a target for 
their actions. is well known that two cyclooxygenase products. 
prostaglandin E2 and prostacyclin, are powerful elevators of cyclic AMP in rat 
peritoneal macrophages. Of these two m.etabolites mentioned, prostaglandin E2 
was shown to be the major metabolite, at least in rat macrophages30 (vide 
chapter 6.1). Elevation of cyclic AMP is associated with an inhibition of 
several functions of macrophages. Thus, inhibitory actions of prostaglandin E2 
cell motility191 , have been 
I a-antigen 
observed on chcmiluminescence197 , phagocytosis 
expression156 •240 , interleukin-1 production42 , cytotoxicity176 •246 
plasminogen activator release226 and complement production159 . In contrast, 
prostaglandin E2 induces collagenase product~on by macrophages257 Although a 
substantial number of reports has been published on the effects of lipoxygenase 
products on a variety of tissues and cells (vide chapter 2, table 1), there is a 
scarcitY of data on the actions of these metabolites on macrophages. It has 
been reported that leukotriene c 4 induces a respiratory burst
121 
and that 
5-hydroxyeicosatetraenoic acid e~~ances !a-antigen expression240 . Both factors 
are markers of enhanced cell activity. It was further demonstrated that 
leukotriene c 4 and leukotriene D4 augmented the release of cyclooxygenase 
metabolites from macrophages88 •89. These latter observations are of particular 
interest since the possibility was raised that macrophage activity is regulated 
via interaction between lipoxygenase and cyclooxygenase derived products. 
With the experiments described in this chapter the interaction between 
leukotriene c 4 and prostaglandin E2 in modulating macrophage activity was 
investigated. using lysosomal enzyme release as a marker of cell activity. 
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Table 1. Effects of Jeukotriene Cq. on resident macrophages. 
LTC 4 (M) 0 1 o-
9 10- 8 10- 7 10-G 
• PCE
2 
(pmoles/ 4.19 ± n.d. 4. 73 ± 3.38 ± 25.38 ± 
1 o6 cells) 0.42 1.10 1. 08 2.28 
TxB 2 (pmoles/ [1..35 ± 3. 95 ± [1..83 ± 6.52*± 9.48*± 
10 6 cells) 0.38 0.21 0.21 0.38 0.51 
GUR (mU/ 0.86 ± 1. 00 ± 1.32*± 1. 63*± • 1. 92 ± 
1 o6 cells) 0.03 0.05 0.05 0.07 0.09 
Table 1. Effects of leukotriene c 4 (LTc4 ) on the release of prostaglandin E2 
(PGE2 ), thromboxane B2 (TxB2 ) and $-glucuronidase ~rom resident macrophages. 
2.5x106 cells were incubated during 1.5 hat 37°C in a humidified atmosphere 
containing 5% C0 2 in air. Macrophages in suspension were exposed to LTC4 , the 
concentration varying from 10-9 to 10-6 M. Note that GUR release was augmented 
by a lower concentration of LTC4 than that needed to stimulate PGE2 and TxB2 
production. Means ± SEM (n~5), • P<0.01 vs. controls (Student's t-test, two 
tailed). 
0 -9 -8 -7 -6 0 -9 -8 -7 -6 
log dose LTC 4 (M) 
0 -9 -8 -7 -6 
GUR 
4 
3 "' 
• 2 ~0 
0 
0 
::> 
E 
Figure 1. Effects of leukotriene c4 (LTC4 ) on the release of prostaglandin E2 , (PGE2 ). thromboxane B2 (TxB2 ) and $-glucuronidase (GUR) from macrophages 
elicited with carrageenan (2 mg i.p., open bars) or with Freund's incomplete 
adjuvant (2 ml i.p., hatched bars). Whereas GUR release and PGE2 production 
could be augmented by LTC4 , TxB2 production was decreased. Experimental 
conditions as described in the legend to table 1. Means± SEM (n~5), •P<0.01 
(Student's t-test, two tailed). 
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2 LEUKOTRIENE C4 INDUCES LYSOSOMAL ENZYME RELEASE AND 
PROSTAGLANDIN E2 PRODUCTION 
The exposure of resident macrophages to leukotriene c4 
lor..r (<10-7 M) 
resulted in the 
of follor..ring alterations (table 1). 
leukotriene c4 there r..rere no changes 
presence of 10-6 M leukotriene C4 
r..rith the effects of arachidonic 
concentrations 
in prostaglandin E2 levels but ln the 
a 6.1-fold increase was observed. In common 
acid on the release of cyclooxygenase 
metabolites a preferential increase of prostaglandin E2 production compared to 
thromboxane A2 was found in response to lcukotriene c4 • Whereas basal levels of 
-6 both metabolites were broadly the same, 10 M leukotriene c4 only induced a 
2.2-fold increase of thromboxane A2 production. Lysosomal enzyme 
($-glucuronidase) release was dose dependently enhanced. It is of particular 
interest that the observed P-glueuronidase release was auemented by a lower 
concentration of leukotriene c4 than that needed to stimulate prostaglandin E2 
release. 
Elicited macrophages shoved a somewhat different response to leukotriene c4 
resident macrophages, prostaglandin E2 and (figure 1). As was found with 
$-glucuronidase release could be augmented by leukotriene c 4 . Again changes in 
lysosomal enzyme release were observed at lower concentrations of leukotriene c 4 
than necessary to enhance prostaglandin E2 production. However, in contrast to 
the increased prostaglandin E2 production, thromboxane A2 release markedly 
decreased. Although absolute values differed between the two elicited cell 
populations (carrageenan elicited macrophages consistently produced more 
cyclooxygenase metabolites and less $-glucuronidase) similar directional changes 
in response to leukotriene c 4 were observed. 
A preferential increase in prostaglandin E2 production from elicited 
macrophages under the influence of leukotriene C4 has been shown earlier by 
Feuerstein et a1. 89 . In contrast to this report, the present study showed that 
the increased prostagl~~din E2 production was associated with a decreased 
production of thromboxane A2 . The observed directional changes between the two 
cyclooxygenase products remains a question to be solved. This event was highly 
- 54 -
reproducible, in addition a similar effect was described with respect to the 
leukotriene induced release of cyclooxygenase products from the guinea pig 
trachea60 . A differential effect of leukotriene c 4 on thromboxane synthetase 
and prostaglandin E isomerase cannot be excluded. Also, the existence of at 
least two different pools of arachidonic acid, which can be activated by 
leukotriene c 4 as was 
observed difference274 . 
shown in our 
Re-evaluating 
laboratory could be responsible for the 
the data from Feuerstein's report 
disclosed some remarkable differences between this study and the results 
presented here. Firstly, the concentration of leukotriene c 4 used in 
Feuerstein's experiments to induce 
suspension was higher than 10-6 M. 
thromboxane ~ synthesis from macrophages in 
At 10-6 M or less, no effect or an actual 
inhibition ot thromboxane A2 release was observed. Secondly, the effects of 
leukotriene c 4 on the production of cyclooxygenase metabolites were found to be 
most prominent in macrophages in monolayer. The macrophages were allowed to 
adhere for 24 hours, without addition of the in vivo eliciting agent. It has 
been shown that removal of the stimulus unblocks the cyclooxygenase and allows 
prostaglandin E2 synthesis, hence deactivation occurs and a cell with properties 
of a r~sident macrophage remains 192 . The results obtained by Feuerstein and 
coworkers with macrophages in monolayer are in agreement with the results 
obtained with resident macrophages in the present study. 
In the present experiments it was shown that leukotriene c 4 enhances 
lysosomal enzyme release, which supports the idea that lipoxygenase products of 
arachidonic acid crucially involved in macrophage activation. 
Circumstancial evidence for a role of lipoxygenase products can be found in the 
effects of lipoxygenase inhibitors on macrophage activity. It has been shown 
that lipoxygenase inhibitors reduce: Ia-antigen expression 
formation 156 , chemiluminescence 164, 197, 
and macrophage 
interleukin-1 mediated 
release69 
granuloma 
and endotoxin induced thromboplastin production58 . 
concentration of leukotriene c 4 necessary to increase 
The fact that the 
prostaglandin E2 
production by macrophages was higher than the one necessary to augment lysosomal 
enzyme release, combined with the observations that prostaglandin E2 depresses 
macrophage activity, raised the possibility that macrophage activity is 
regulated via an interaction between lipoxygenase and cyclooxygenase derived 
products. Leukotriene c 4 being stimulatory and prostaglandin E2 suppressive, 
the balance between these two products would determine the degree of macrophage 
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ac~ivi~y and reprcBen~ a mechanism by vhich arachidonic acid oxygena~ion 
produc~s can con~rol inflammatory/immune reactions. The folloving sections of 
~his chapter prcscn~ the results of experiments vhich vere aimed at unravelling 
this interaction. In these experiments the effects of cyclooxygenase inhibitors 
and prostaglandin E2 on the leukotriene c4 induced 2-glucuronidase release vcrc 
inve:::~igated. 
3 CYCLOOXYCENASE INHIBITORS MODULATE THE LEUKOTRIENE c4 
INDUCED LYSOSOMAL ENZY'ME RELEASE 
The effects of four cyclooxygenase inhibitors, indomethacin, aspirin, 
piroxicam and Org 7258 on the release response of carrageenan elici~ed 
macrophages vcre studied. In ~he absence of leukotriene c4 all cyclooxygenase 
inhibitors effectively blocked the release of cyclooxygenase metabolites vithout 
affecting lysosomal enzyme release (table 2). The relative order of potency 
vas: Org 7258 indomethacin > piroxicam aspirin. Differential effects of 
~he four cyclooxygenase inhibitors could be observed in the presence of 
leukotriene c4. 
Indomethacin 
Figure 2a shovs that exposure of the cells to 10-B M leukotriene c4 
resul~ed ~n enhanced prostaglandin E2 production. decreased thromboxane A2 
production and increased release of ~-glucuronidase. These effects vere more 
pronounced in the presence of 10-6 M leukotriene c4 (figure 2b). In both cases 
the leukotriene c4 induced E-glucuronidase release vas dose dependently 
augmented by the addition of indomethacin vhereas the enhanced prostaglandin E2 
production vas blocked and the already diminished thromboxane A2 production vas 
further declined. 
Aspirin 
Aspirin vas found to be slightly less potent than indomethacin in 
augmenting the leukotriene c4 induced lysosomal enzyme release and in blocking 
the biosynthesis of endogenous prostaglandins (figure 3). 
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Table 2. Effects of cyclooxygenase inhibitors on the release of PGE2, 
TxB 2 and CUR from carrageenan elicited macrophages. 
PGE26 Tx8 2 CUR 
treatment pmoles/10 Mo. pmoles/1 o6 Mo. mU/10 6 Mo. 
controls 1.10:!.::0.10 1.58 ± 0.04 1.06 ± 0.09 
+10- 7 M indom. 1.16 ± 0.08 1.09 ± 0.09 0. 94 ± o. 07 
+10- 6 M indom. 0.62 ± 0.10 0. 79 ± 0.05 1.16 ± 0.05 
+ 10- 5 M indom. 0.22 ± 0.02 0.29 ± 0.01 1.09 ± 0.11 
+10- 4 M indom. O.lll-±0.02 0.25 :t 0.02 1.27 ± 0.06 
controls 1.31 ± 0.06 1.52 ± 0.10 1.11 :t 0.08 
-6 
+ 10 M aspir. 1.32 :t 0.09 1.52 ± 0.10 1.39±0.16 
-5 
+ 10 M aspir. 1.03 ± 0.03 0.64 ± 0.03 1.29 :t 0.13 
+ 10-Q. M aspir. 0.71±0.06 0.32 ± 0.04 1.43 ± 0.09 
controls 1.93±0.17 3.57 ± 0.12 0. 74 ± 0.03 
-8 
+ 10 M pirox. 2.08 :t 0.19 3.20 ± 0.10 0.61 :!.:: 0.06 
-7 
+ 10 M pirox. 2.29 ± O.Oll- 2.ll-ll.±0.22 0. 71 ± O.Oll-
+ 10-6 M pirox. 1.05 ± 0.04 1.95 ± 0.05 0.68 :t 0.05 
controls 1.53 :t 0.13 3.51:!.:: 0.12 0.64 :t 0.04 
-8 
+ 10 M Org 7258 1.12 ± 0.09 1.65±0.17 0.64 ± 0.06 
-7 
+ 10 M Org 7258 0.41 ± 0.02 0.42±0.02 0. 76 ± 0.06 
+ 10- 6 M Org 7258 0.17 ± O.Oll- 0.39 :t 0.03 0.59 ± 0.04 
Table 2. Effects of the cyclooxygenase inhibitors 
piroxicam and Org 7258 on the release of prostaglandin 
indomethacin, aspirin, 
E2 (PGE2 ), thromboxane B2 
(TxB2 ) and ~-glucuronidase from carrageenan elicited peritoneal macrophages. 
All cyclooxygenase inhibitors effectively reduced the production of PGE2 and 
TxB2 , whereby no effects on GUR release could be observed. Experimental, 
conditions as described in the legend to table 1. Means ± SEM (n:=S). 
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Figures 2/3. Effec~s of indomethacin 
(figure 2) and aspirin (figure 3) on the 
lcukotriene c 4 {LTC4 ) induced release 
response. Figure 2A represents values 
found in the presence of 10-8 M LTC4 , 
figure 2B and figure 3 in the presence 
of 10-6 M LTC4 . Open symbols on the axes 
represent basal secretory levels (no in-
domethacin, aspirin or LTC4 added) of 
prostaglandin E (PGE2 , e), thromboxane 
B2 (TxB2 . a) and ~-glucuronidase (CUR. 
A). No-ce that both indomethacin and as-
pirine augmented the LTC4 induced re-
lease of GUR. Experimen~al condi~ions 
as described in the legend to ~able 1 • 
n=5. * P<O.Ol vs. basal secre~ory 
levels, • P<O.Ol vs. LTC4 induced 
secretory levels (S~udent's ~-~es~. ~wo 
~ailed). 
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prnoles/106 M~. 
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Figure 4. Effects of piroxicam on the 
leukotriene c 4 (10-
6 M) induced release 
of prostaglandin E2 (PCE2 . 0), thrombox-
ane B2 (TxB2 , a), and ~-glucuronidase 
(CUR, A) from carrageenan elicited ma-
crophages. Open symbols on the axes re-
present basal secretory levels {no LTC 4 
added). In contrast with indomethacin or 
aspirin piroxicam did not affect CUR re-
lease. Experimental conditions as des-
cribed in the legend to table 1. Means ± 
SEM (n,5). *P<0.01 vs. basal secretory 
levels, *P<0.01 vs. LTC4 induced se-
cretory levels (Student's t-test, two 
tailed). 
Figure 5. Effects of Org 7258 on the 
leukotriene c 4 (10-
6 M) induced release 
of prostaglandin E2 (PGE2 • o). thrombox-
ane B2 (TxB2 , a) and ~-glucuronidase 
(GUR, A) from carrageenan elicited ma-
crophages. Open symbols on the axes re-
present levels in the absence of LTC4 or 
Org 7258. Note that in contrast to indo-
methacin, aspirin and piroxicam (figures 
2, 3 and 4) Org 7258 inhibits the LTC4 
induced GUR release. -x- P<0.01 vs. basal 
secretory levels, • P< 0. 01 vs. LTC4 in-
duced release (Student's t-test, two 
tailed). Means± SEM (n~5). 
- 59 -
Piroxicam 
Concerning pros~aglandin E2 and ~hromboxane A2 produc~ion similar resul~s 
as ~hose ~ound wi~h indomc~hacin and aspirin were observed wi~h piroxicam. Wi~h 
respec~ ~o ~-glucuronidase release, in con~ras~ ~o indome~hacin or aspirin, 
piroxicam did no~ augmen~ ~he leuko~:-iene c4 induced release (~igure. 4). 
Whe~her ~he observed difference is 
no~ be es~ablished. Increasing 
due ~o a differcn~ mech~~ism o~ ac~ion could 
~he dose beyond 10- 6 M caused damage ~o ~he 
membranes of ~he macrophages, as could be observed by an enhanced release of ~he 
cy~oplasmic enzyme lac~a~e dehydrogenase. 
Org 7258 
A marked dif~erence be~ween ~he ac~ions of indome~hacin or aspirin on ~he 
one side and Org 7258 on ~he o~her hand could be observed wi~h respec~ ~o 
lysosomal enzyme release. Whereas indome~hacin and aspirin augmen~ed ~he 
leuko~ricne c4 induced release, it was inhibi~ed by Org 7258. No~ only ~he 
leuko~riene c4 induced ~-glucu:-onidase release could be reversed by Org 7258 bu~ 
i~ also res~ored ~he increased pros~aglandin E2 produc~ion (~igure 5). 
The fac~ ~ha~ indome~hacin and aspirin enhanced the leuko~riene c4 induced 
lysosomal enzyme release provides ~ur~her proo~ for ~he hypo~hesis ~ha~ 
endogenous pros~aglandins may func~ion as inhibi~ory feed-back regula~ors of 
macrophage activation. With respect to the ef~ects of cyclooxygenase inhibi~ors 
on macrophage activity several reports have been published. Two earlier reports 
showed that indomethacin did 
o~ lysosomal enzymes22 • 169 . 
not af~ect or decrease the zymosan induced release 
indomethacin 
In ~hese 
were used of 10-3-10-4 M. 
studies however, concentrations of 
Next to inhibiting cyclooxygenase these 
concen~ra~ions are now known to have two other effects: inhibition of 
lipoxygenase and inhibition of phosphodiesterase. The s~imulus used in ~hese 
studies (zymosan) is known to induce leukotriene release from macrophages and it 
has been sU&?ested that the zymosan induced lysosomal enzyme release was 
leuko~riene mediatcd25 . Therefore inhibition of lipoxygenase activity by high 
doses of indomethacin will lead to reduced lysosomal enzyme release. Also 
inhibi~ion of phosphodiesterase has the same effect (vide chapter 6.4). In ~'1 
elegant study performed by Schnyder and coworkers, the effect of indome~hacin on 
plasminogen activator release was studied226 . It was found that indomethacin 
enhanced the degree of activation obtained after zymosan phagocy~osis. Addition 
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Figure 6. Modulation of the release of thromoboxane B2 {TxB2 ) and 
~-glucuronidase (GUR) and of intracellular cyclic AMP (cAMP) content of 
carrageenan elicited macrophages by leukotriene c 4 and prostaglandin E1 (PGE1 ). 
Open bars represent values found in the presence of prostaglandin Eg alone, 
hatched bars in the presence of 10-6 M leukotriene c4 and 10- -10-
6 M 
prostagl~~din E1 . Whereas, in the absence of leukotriene c4 , PGE1 had no 
effects, in the presence of leukotriene c4 the level of intracellular cAMP was 
enhanced and the leukotriene c4 induced CUR release could be reversed. Both 
PCE1 and LTC4 caused a diminished TxB2 production. Experimental conditions as 
described in the legend to table 1. • P<0.01 vs. values observed in the 
presence of leukotriene c 4 (Student's t-test, two tailed). Means± SEM (n=5). 
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o£ exogenous prostaglandin E2 on the other hand, had the opposite effect. it 
suppressed the enhanced plasminogen activator release induced either by 
indomethacin, zymosan or a combination of both. Futher evidence in favour of a 
regulatory role of endogenous prostaglandins was obtained from the following 
results. Cyclooxygenase inhibitors have been shown to enhance macrophage 
activity resulting in augmentation of: Ia-antigen expression156 , bactericidal 
activity and interleukin-1 secretion42 and tumoricidal activity43 . 
The results obtained in the present experiments underline a distinctive 
nature of Org 7258 relative to other non-steroidal anti-i4flammatory drugs. 
Org 7258 blocked the leukotriene c 4 induced lysosomal enzyme release. Since 
this property was not shared by the other cyclooxygenase inhibitors studied, it 
is concluded that the blockade of lysosomal enzyme release is independent of the 
inhibition of cyclooxygenase. It has previously been reported that Org 7258 
suppressed the zymosan induced secretion o£ the lysosomal enzyme ~-glucuronidase 
from mouse peritoneal macrophages. This activity was paralleled by 
dinitrophenol, a well-known uncoupler o£ oxidative phosphorylation, indicating 
that this mechanism may be implicated in the ef£ect of Org 7258 on lysosomal 
enzyme release. Altho~· a number of studies have indicated that Org 7258 is a 
potent ~~ti-inflammatory agent in several animal models, including the 
~anuloma-thymus model, the carrageenan induced paw oedema model and the 
calcium-pyrophosphate induced pleurisy, the exact mechanism of action of the 
drug is not clear yet (Den Hollander. personal communication). 
4 PROSTAGLANDIN E1 AND PROSTAGLANDIN E2 suPPRESS THE LEUKOTRIENE c4 
INDUCED LYSOSOMAL ENZYME RELEASE 
In a seperate set of experiments the effects of prostaglandin E1 and 
prostaglandin E2 on macrophage activity were tested. Prostaglandin E1 was shown 
to have the following effects (figure 6). It should be noted that due to the 
addition of prostaglandin E1 • the measurement of prostaglandin E2 was unreliable 
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Figure 7. E~fects of leukotriene C4 (LTC4 ), indomethacin and prostaglandin E2 
(PGE2 ) on ~-glucuronidase (GUR) release from carrageenan elicited macrophages. 
Open bars represent the values which were found in the absence (first panel) or 
presence of 10-8 M (second panel) or 1o-6 M LTC4 (third panel). Pretreatment of 
the cells with indomethacin (dotted bars) (10-5 M) resulted in an augmented GUR 
release. Addition of 10-? M PGE2 (hatched bars) prior to LTC4 prevented the 
LTC4 induced GUR release (second and third panel) or, in the absence of LTC4 
(first panel) diminished the release. This effect was blocked when the cells 
were pretreated with indomethacin (closed bars) before 
Experimental conditions as described in the legend 
basal levels (no drugs added) (Student's t-test, two 
(n=5). 
LTC4 or PGE2 were added. 
to table 1. • P<0.01 vs. 
tailed). Means ± SEM 
- 63 -
because of cross-reactivity with the antibody used in the radioimmunoassay. 
Therefore no data on prostaglandin E2 production are supplied with respect to 
this eXperiment. In the absence o< leukotriene c4 no effects o< 
prostaglandin E1 could be observed, except on thromboxane A2 production. 
Already at the lowest concentration of prostaglandin E1 tested, thromboxaie A2 
production was inhibited, whereby no further decrease could be established by 
increasing the concentration of prostagla~din E1 . In the presence of 10-6 M 
leukotriene c4. variations in all three parameters were observed. The 
leukotriene c 4 induced $-glucuronidase release was dose dependently reversed 
whereby the normal basal secretory level was restored. Thromboxane A2 
production, already inhibited by leukotriene c 4 • was further depressed. Whereas 
prostaglandin E1 by itself had no effect on intracellular cyclic AMP levels, in 
the presence of leukotriene c 4 this level was enhanced by addition of 10-
7 M 
prostaglandin E1 . 
Prostaglandin E2 was tested in a single dose, which was known to elevate 
intracellular cyclic AMP in this system. The results of these experiments are 
shown in figure 7. In contrast with prostaglandin E1 • prostaglandin E2 (10-
7 M) 
reduced basal release of P-glucuronidase. an effect which was prevented when 
indomethacin (10-5 M) was added prior to pros~aglandin E2 . A dose dependent 
increase o< $-glucuronidase release was observed following addition of 
leukotriene c 4 . Again this increase could be markedly enhanced by pretreating 
the cells with indomethacin. Prostaglandin E2 completely blocked the enhanced 
10- 6 M release caused by leukotriene c 4 • however in the presence o< 
leukotriene c 4 and 
The results 
indomethacin this blockade was only partial. 
of the present work demonstrate that prostaglandin E1 
suppressed both thromboxane A2 synthesis and leukotriene c 4 induced lysosomal 
enzyme release. It was also shown that the latter effect was shared by 
prostaglandin E2 . Depressed thromboxane A2 production, induced by 
prostaglandin E2 has been described previously
78
•
90
. In these studies the 
effects of prostaglandin E2 have been attributed to activation of adenylate 
cyclase activity. Since prostaglandin E1 was shown to induce cyclic AMP 
generation, the present experiments seem to confirm this idea. However. as will 
be discussed in chapter 6. enhanced cylic AMP levels, induced either by 
e2-adrenoceptor stimulation or by deactivation of phosphodiesterase have 
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different effects on thrornboxane A2 production. Stimulation of ~2 -adrenoceptors 
was followed by a reversal of the inhibition of thrombox~~e A2 production due to 
leukotriene c 4 whilst inactivation of phosphodiesterase resulted in only a 
modest inhibition of thromboxane A2 production. In contrast, a decreased 
lysosomal enzyme release was induced by both treatments and was related to an 
increase in cyclic AMP levels. Whether the effects of prostaglandins E on 
thromboxane A2 metabolism are due to a direct effect on thromboxane synthetase, 
to interference at a specific site rendering the cell unresponsive in terms of 
thromboxane A2 synthesis or to activation of adenylate cyclase is not clear yet. 
Elucidation of the interactions between prostaglandin E2 • thromboxane A2 and 
cyclic AMP will provide insight into the normal regulation of the release and 
effects of these metabolites and the mechanisms by which they modulate 
macrophage activity. 
It has been postulated that endogenous prostaglandins do not play a major 
role in regulating lysosomal enzyme release from macrophages169. However, the 
fact that exogenous prostaglandin E2 reduced the basal release, abolished the 
leukotriene c 4 induced release counteracted the augmentation by 
indomethacin of the leukotriene c 4 induced release, strongly indicate that 
prostaglandins are involved in the regulation of lysosomal enzyme release. 
Furthermore they support the hypothesis that lipoxygenase-
cyclooxygenase-derived products interact in modulating macrophage activity. The 
fact that prostaglandin E2 could not completely reverse the leukotriene c 4 
induced £-glucuronidase release in the presence of indomethacin can be explained 
by the inability of leukotriene c 4 to induce prostaglandin E2 production in this 
situation. In the absence of indomethacin leukotriene c 4 causes macrophages to 
produce prostaglandin E2 which will act synergistic with the exogenously added 
prostaglandin E2 , resulting in a full reduction of leukotriene c 4 induced 
~-glucuronidase release. 
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5 PROSTAGLANDIN E2 FAILS TO AFFECT LEUKOTRIENE SYNTHESIS 
Recently, inhibition by prostaglandin E2 of leukotriene B4 release from 
activated neutrophils was reported116 In order to establish whether a similar 
relation exists in macrophages, the effect of prostaglandin E2 on Ca-ionophore 
induced leukotriene production was studied- As can be seen in table 3. 
prostaglandin E2 in a concentration of 10-? M did not affect leukotriene B4 nor 
leukotriene c4 
elicited cells 
synthesis from Freund's 
with one exception. The 
incomplete adjuvant or 
A23187 (10-6 M) induced 
carrageenan 
release of 
leukotriene c4 from Freund's incomplete adjuvant elicited macrophages could be 
reduced by prostaglandin E2 . Whether this difference really is valid (the 
standard deviation of this point is extraordinarly small) is not clear yet. In 
Table 3. Effects of prostaglandin E2 on leukotriene production. 
A23187 [M) 0 10- 8 10- 7 10- 6 
LTC 4 CAR.Mo. 3.85 
" 
0.20 4.08 ± 0.37 4.62 ± 0.46 5.51 
" 
0.42 
+ 10-7 M PGE
2 3.51 ± 0.31 4.32 ± 0.41 4.89 ± 0.52 5.39 ± 0.37 
FIA.Mo. 4.55 ± 0.33 4.43 
" 
0.63 5.28 
" 
0.43 6.55 
" 
0.38 
+10- 7 M PGE
2 4.35 ± 0.27 4.78 " 
0.29 5.43 ± 0.41 5.63 
" 
0.09 
LTB 4 CAR.Mo. 18. 51 ± 1.47 2!1.80 ± 1. 93 58.04±4.17 
+10-7 M PGE
2 19.53 
" 
2.01 22.84 ± 2.17 51.62 ± 6.38 
FIA.Mo. 13.04 
" 
1. 08 34.66 
" 
2.75 
+ 10- 7 M PCE
2 16.08 " 
2.16 32.50 
" 
3.14 
Toblo 3. Effects of prostaglandin E2 on the (A23187-stimulated) release of 
leukotriene c4 and B4 from carrageen~~ (CAR) or Freund's incomplete adjuvant 
(FIA) elicited macrophages. No effects of prostaglandin E2 on leukotriene 
release could be observed. 10x1o6 cells in 10 ml were incubated for 15 minutez 
at 37°C in a humidified atmosphere containing 5% co2 in air, in the presence of 
10 #g arachidonic acid ~~d 2 mM glutathione. Means ± SEM Cn~4). Leukotriene 
production is expressed as pmoles/10 6 cells. 
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order to clarify this matter further experiments will have to be carried out, 
including a dose response curve of prostaglandin E2 in the absence or presence 
of cyclooxygenase inhibitors. Furthermore these experiments will have to be 
extended to resident macrophages. Possibly, the reduced lipoxygenase activity 
in elicited macrophages is to be held responsible for the lack of effect of 
prostaglandin E2 . However, we could observe no effect of prostaglandin E2 on 
leukotriene production in a preliminary study using resident macrophages. 
6 SUMMARY AND CONCLUSIONS 
The effects of leukotriene c4 and prostaglandin E2 on macrophage activity 
were studied, for which lysosomal enzyme release was taken as a criterion. It 
was shown that leukotriene c4 induces a release response consisting of enhanced 
prostaglandin E2 and ~-glucuronidase release in elicited and resident cells. 
Thromboxane A2 production was increased in resident cells but inhibited in 
elicited macrophages. Furthermore it was shown that the concentration of 
leukotriene c4 necessary to increase prostaglandin E2 production was higher than 
the one necessary to augment lysosomal enzyme release. This observation, 
combined with observations that prostaglandin E2 depresses diverse aspects of 
macrophage activity, raised the possibility that macrophage activity is 
regulated via interactions between lipoxygenase- and cyclooxygenase-derived 
products. In conclusion: in vitro activation of macrophages with a low dose of 
leukotriene c4 leads to enhanced lysosomal enzyme release, higher doses result 
in a preferential production of pro~taglandin E2 as compared to thromboxane A2 • 
whereby thromboxane A2 production was inhibited in elicited macrophages. 
Inhibiting the synthesis of endogenous prostaglandins by preincubating the 
macrophages in the presence of cyclooxygenase inhibitors resulted in modulation 
of the leukotriene c4 induced $-glucuronidase release. The relative order of 
potency, in terms of inhibiting cyclooxygenase activity was: Org 7258 > 
indomethacin > piroxicam > aspirin. Indomethacin and aspirin were shown to 
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augmen~ leukotriene c 4 induced lysosomal enzyme release, piroxicam was 
ineffective and Org 7258 inhibited ~-glucuronidase release. The observation 
that indomethacin and aspirin enhanced leukotriene c 4 induced lysosomal enzyme 
release provides further proof for the hypothesis that endogenous prostaglandins 
~ay function as inhibitory feedback regulators of macrophage activity. Since 
piroxicam was found to be toxic beyond a concentration of 10-6 M, it could not 
be established whether the ineffectivity of piroxicam was due to a different 
mode of action or to too low a concentration. In contrast wi~h aspirin and 
indomethacin. the experimental drug Org 7258 inhibited lysosomal enzyme release 
induced by leukotriene c 4 . The possibility was raised that this effect of 
Org 7258 was due to uncoupling of oxidative phosphorylation. In conclusion: 
the cyclooxygenase inhibitors aspirin and indomethacin augment leukotriene c 4 
induced lysosomal enzyme release, probably by blocking endogenous prostaglandin 
production; the experimental drue Org 7258 has the opposite effect. 
Exogenously added prostaglandin E1 or E2 could reverse the leukotriene c, 
induced ~-glucuronidase release. Furthermore it was shown that prostaglandin E2 
reduced basal .a-glucuronidase release and counteracted the augmentation by 
indomethacin of the leukotriene c 4 induced lysosomal enzyme release. These 
facts are strong indicators that prostaglandins are involved in regulating 
macrophage activity. Leukotriene c 4 being stimulatory and prostaglandin E2 
suppressive. the balance between these two products would determine the degree 
of macrophage activity and represent a mechanism by which eicos~~oids can 
control inflammatory/immune reactions. In conclusion: exogenous 
prostaglandin E2 reverses lysosomal enzyme release induced by leukotriene c 4 
and/or indomethacin. 
In view of the 
prostaglandin E2 in 
proposed 
modulating 
interac"t:ion 
macrophage ac"t:ivity, 
proztaglandin E2 on the release of leukotrienes from 
leukotriene c4 
the effect 
mac:rophages 
investieated. Prostaglandin E2 did not affect leukotriene B4 or leukot:riene c 4 
production by elicited macrophages. In conclusion: prostaglandin E2 • in the 
dosage studied, has no effect on leukot:riene synthesis by elici~ed macrophagcs. 
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CHAPTER 6. INVOLVEMENT OF CYCLIC AMP IN THE REGULATION 
OF MACROPHAGE ACTIVITY. 
1 INTRODUCTION 
Extensive studies of leukocytes have documented the inhibitory role of 
cyclic AMP as an intracellular -second messenger-, relaying a stimulus from the 
extracellular environment to biochemical machinery within the cell. The -first 
messenger- may be a chemical change in the cell's environment but is represented 
in more complex situations by neurotransmitters or hormones which activate 
aCenylate cyclase28 • 100 With respect to macrophages. of these hormones 
prostaglandins are of particular interest. Elevation of intracellular cyclic 
AMP levels in response to prostaglandin E2 . associated with an inhibition of 
several macrophage functions, has been observed in a number of studies (vide 
chapter 3.1). Prostacyclin also stimulates the production of cyclic AMP in 
elicited peritoneal macroph~es24 . However, in contrast to prostaglandin E2 . 
prostacyclin failed to reduce the macrophage mediated component of a carrageena~ 
induced granuloma196 . At the time of the above studies, the reasons for the 
observed differences between prostaglandin E2 and prostacyclin were poorly 
understood. More recent eA~eriments performed in our laboratory revealed that 
in terms of adenylate cyclase activation rat peritoneal macrophages responded 
better to prostaglandin E2 than to a stable synthetic analogue of 
prostacyclin30 . It was also shown that low concentrations of prostaglandin E2 
inhibited the prostacyclin induced elevation of cyclic AMP 6 , an effect which was 
mediated via displacement of prostacyclin from its receptor by 
prostaglandin E2
189 These findings susgested that the observed low 
respons~veness of rat granuloma or peritoneal macrophages to prostacyclin was 
due to perma~ent exposure of these cells to endogenous prostagla~din E2 . They 
also suggected tha-... prostaglandin E2 has a dominant role in the control of 
cyclic AMP in rat macrophagec. 
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Figure 1. Beta-adrenoceptor agonists reverse the leukotriene c 4 induced release 
of prostaglandin E2 (PGE2 , e). thromboxane B2 (TxB2 , •) and ~-glucuronidase 
(GUR, A) from carrageenan elicited macrophages. 2.5x106 cells/ml were incubated 
for 1.5 h at 37°C in a humidified atmosphere containing 5% Co2 in air, in the 
presence of 10-6 M leukotriene c 4 (closed symbols). Open symbols represent the 
values as were found when the cells were not exposed to any drug. Addition of 
the ~2-selective adrenoceptor agonist salbutamol (panel la) or the non-selective ~-adrenoceptor agonist isoprenalin (panel 1b) within the range of 10-6-10-4 M 
effectively reversed the leukotriene c 4 induced release response. ** P<0.02. 
•P<0.01 (Student's t-test, two tailed). Means± SEM (n=o5). 
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The eA~erimen~s described in ~his chapter vere performed vith carrageenan 
elicited macrophages. With respect to adenylate cyclase activity, marked 
differences exist betveen resident and elicited macrophages. Elicited 
macrophages have a depressed prostaglandin E2 synthesising capacity and levered 
intracellular cyclic AMP levels but an enhanced responsiveness of adenylate 
cyclase to exogenously added or endogenously produced prostagland~n E2 30 •80 In 
light of the fact that leukotriene c 4 induces prostaglandin E2 production, vhich 
vas shown to counteract the effects of leukotriene c 4 on macrophage activity, 
combined vith the knovledge that prostaglandin E2 exerts its effects via 
stimulation of adenylate cyclase, the experiments described in this chapter vere 
performed to investigate the involvement of cyclic AMP in the leukotriene c 4 
induced release response. 
2 22-ADRENOCEPTOR STIMULATION REVERSES THE LEUKOTRIENE C4 
INDUCED RELEASE RESPONSE 
Activation of adenylatc cyclase may be achieved through stimulation of a 
variety of adenyla~e cyclase-coupled receptors. Since $-adrenoceptor agonists 
are known to exert their effec~s through stimulation of adenylate cyclase, the 
present study was initiated to investigate the effects of the 2-adrenoceptor 
agonists salbu~amol 
response. In the 
and isoprenalin on the leukotriene c 4 induced release 
study the $-adrenocep~or antagonists sotalol. H3525 and 
practolol were also included. 
Neither salbutamol. isoprenalin, practolol, H3525 or sotalol had any effect 
on the basal secretory parameters measured (da~a no~ shown). Addition ot 
leukotriene c 4 (10-
6 M) to the macrophages resulted in increased ~-glucuronidase 
release. enhanced prostaglandin E2 production and inhibition of thrombox~~e A2 
production. Both the selective e 2-adrenoceptor agonist salbutamol (figure 1B) 
and the non-selective e-adrenoccptor agonist isoprenalin (figure 1A). within tr.e 
f -6 -4 1 concentration range o 10 -10 M. dose-dependently reversed the eukotriene c 4 
- 72 -
%change vs. controls %change vs. controls 
.. 
2a 2b + 
150 150 
100 100 
50 50 
0 0 
GUR 
50 50 
%change vs. controls %change vs. control~ 
.. 
3a 3b + 
150 150 
100 100 
so l.r. so 
Inn 0 0 
GUR GUR 
50 50 
- 73 -
Table 1. Effects of isoprenaline and practolol on the Ieukotriene c 4 induced 
release response from carrageenan elicited macrophages. 
PGE 2 TxB 2 GUR 
pmo!es/106 Mo. pmoles/1 06 Mo. mU /106 Mo. 
1. controls 1.54::!: 0.07 1.72:!: 0.13 1.32 ± 0.13 
2. + LTC 4 (10-
6 M) 3.54:!: 0.29 0.84:!: 0.07 2. 92 ± 0.30 
3. as 2 +isoprenaline (l0- 5 M) 1.89:!:0.06 1.39:!: 0.09 1. 81 ± 0. 16 
4. as 3 + practolol (10- 6 M) 2. 11 ± 0.11 1.31 ± 0.09 1. 73 :!: 0.12 
5. as 3 + practolol (10- 5 M) 2.03 ± 0.06 1.43 ± 0. 10 1.69:!: 0.15 
6. as 3 + practolol (10- 4 M) 2.08 ± 0.09 1.46 ± 0.12 1.80:!:0.16 
Table 1. Effects of the 2 1-selective adrenoceptor agonist practolol on the 
interaction between leukotriene c4 (LTC 4 ) and the non-selective e-adrenoceptor 
agonist isoprenalin. The LTC4 induced release response could be reversed by 
isopenalin (To-5 M). Addition of practolol within a concentration range of 
10-6-10-4 M was without any effect on the interaction between LTC4 and 
isoprenalin. Experimental conditions as described in the legend to figure 1. 
Means ± SEM (n:5). 
Figures 2/3. Effects of the non-selective P-adrenoccptor antagonist sotalol 
(figure 2) and the e2-selective antagonist H3525 (figure 3) on the interactions 
between P-adrenoceptor agonit::ts and leukotriene c4 {LTC4 J. Responses are 
expressed as percentages change vs. controls (no drugs added. :0%). The 
release response, induced by LTC4 (10-
6 M, hatched bars) of prostaglandin E2 , 
thromboxane B2 and 2-glucuronidase was reversed by the e-adrenoceptor 
(dotted bars) salbutamol (10- 5 M, panel 2a/3a) or isoprenalin (10-5 M. 
Addition of sotalol or H3525 {open bars) within the concentration 
10- 6 -10-4 M dose dependently restored the LTC4 induced release 
Experimental conditions as described in the legend to figure 1. 
(Studer.t's t-test. two tailed). Means± SEM {n=5l· 
agonists 
2b/3b). 
range of 
response-
• P<O.Ol 
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induced release response. Minimal differences were observed between the effects 
of salbutamol and isoprenalin. Whereas salbutamol was more effective in 
blocking the effects of leukotriene c4 on prostaglandin E2 and $-glucuronidase 
release, isoprenalin was more effective on thromboxane A2 production. The 
actions of salbutamol and isoprenalin could be blocked by different agents known 
to have s-adrenoceptor blocking properties, such as sotalol (figure 2), a 
non-selective antagonist, and the experimental drug H3525 (figure 3) which was 
reported to be Practolol, a selective $1-adrenoceptor 
antagonist failed to reverse or to reduce the inhibition of the leukotriene c 4 
induced release response caused by isoprenalin (table 1). 
Though these results support the view that $2-adrenoceptors are present on 
macrophage membranes and that activation of these receptors can down-regulate 
macrophage activity, the final evidence that these receptors are present has not 
been furnished yet. For this purpose binding studies with radioactive ligands 
will have to be carried out. However modulation of macrophage activity, as was 
shown in the present study, may represent a mechanism by which s-adrenoceptor 
agonists can control inflammation. Contradictory reports on the role of 
s-adrenoceptors in macrophages have been published. Schultz and coworkers229 
tested a number of agents known to increase intracellular cyclic AMP levels. 
The s-adrenoceptor agonist, isoprenalin, was without any effect on activated 
macrophage functions at all concentrations tested. This observation was similar 
to that of Kurland and associates 158 , who showed that the proliferation of 
macro~hage progenitor cells was not inhibited by s-adrenoceptor agonists and 
suggested that these cells lacked s-adrenoceptors. More recently however. it 
was found that L-isoprenalin inhibited the phagocytosis of Trypanosoma cruzi by 
mouse peritoneal macrophages268 and activated adenylate cyclase in membrane 
preparations or intact macrophages254 . It was also found that L-isoprenalin 
decreased the lymphokine induced aggregation of macrophages; D-isoprenalin had 
no effect216 . Possibly a difference between D- and L-isoprenalin could explain 
the observed variation. Schultz and Kurland do not indicate whether they used 
D- or L-isoprenalin, whereas a racemic mixture was used in the present 
experiments. 
Another factor which is of importance in determining the reaction of 
macrophages to $-adrenergic stimulation is their ~state of activity- or their 
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pathophysiological state. Whereas tho present study indicates that 
~~adrenoceptor agonists do not inhibit macrophage basal secretions, but do 
abolish the effects of a stimulatory agent, the converse was shown in a paper by 
Vogel and coworkers255 . They showed that a defective, Fe receptor mediated. 
phagocytosis of opsonized sheep erythrocytes could be corrected by agents known 
to elevate intracellular cyclic AMP. Among these was isoprenalin. On the other 
hand, Fe receptor mediated phagocytosis has been reported to induce cyclic AMP 
synthesis. Although isoprenalin enhanced cyclic AMP levels in the absence of 
phagocytosis, the already increased levels induced by phagocytosis could not be 
further increased by the $-adrenergic agonist 187 . In short, the responses 
controlled by the interaction of catecholamines with $-adrenergic receptors are 
modified through a and pharmacological 
perturbations and are 
variety of physiological factors 
most difficult to standardize264 . 
3 LEUKOTRIENE c4 AND SALBUTAMOL SYNERGIZE IN ELEVATING 
CYCLIC AMP LEVELS 
Carrageenan elicited macrophagcs were preincubated for 15 minutes before 
addition of vehicle. leukotriene c 4 (10-
6 M), salbutamol (10-5 M) or salbutamol 
and leukotriene c 4 . After 1, 5, 10 and 15 minutes the cells were spun down, the 
supernatants were assayed for the presence of prostaglandin E2 and the content 
of intracellular cyclic AMP of the macrophages in the pellet was determined 
(vide Appendix: Materials and Methods for a detailed description of the 
experimental procedures). Changes in cyclic AMP levels are presented ln 
figure 4A, of prostaglandin E2 production in figure 4B. Leukotriene c 4 vas 
found to induce a rapid transient increase of cyclic AMP after minute. Tho 
same effect, though more prono~~ced, was observed with salbutamol. However when 
the macrophages were exposed to a combination of leukotriene c 4 and salbutamol, 
cyclic AMP levels remained enhanced for as long as 10 minutes. 
15 minutes af~er addition, leukotrienc c 4 caused a second rise. If 
compared to control levels each moment, significant changes in 
cAMP 
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Figure 4. Kine~ic changes of intracellu-
lar cyclic AMP levels (figure 4a) and 
prostaglandin E2 production (figure 4b) 
of carrageenan elicited macrophages af-
ter exposure of the cells to LTC4 (open 
bars, e) (10- 6 M), salbutamol (dotted 
bars. •) ( 1 o-5 M) or to the combination 
of' these drugs (hatched bars, .6.). The 
cells were preincubated for 15 minutes 
prior to addition of the drugs. cAMP 
and PGE2 levels were assessed 0. 1, 5. 
10 and 15 minutes after addition of LTC4 
or salbutamol. cAMP values are 
expressed as percentages vs. controls 
(0) (=0~). PGE2 as pmoles/106 cells. 
Means± SEM (n=6). 
-• 
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Figure 5. Kinetic changes of intracellular cyclic AMP levels of carrageenan 
elicited macrophages. Changes were measured 1, 10 and 15 minutes (left, middle 
and right bar of a block of three respectively) after exposure of the cells to 
vehicle (controls), LTC4 (10- 6 M), salbutamol (10-5 M) or to a combination of 
~hese two drugs. Furthermore the values were measured in the absence (open 
bars) and presence of 10- 5 M indomethacin (hatched bars). The cAMP generation, 
induced by LTC4 after 1 and 15 minutes. could be blocked by indomethacin. In 
contrast, salbutamol-mediated cAMP generation was prolonged after pretreatment 
with indomethacin, an effect which was even more pronounced when salbutamol and 
LTC 4 ""'ere both added to the cells. Experimental conditions as described in the 
legend to figure 4. 
controls, *P<0.01, 
*P<0.01 vs. 
indomethacin 
controls,* P<Q.01 vs. indomethacin treated 
treated vs. non-treated within each group 
(Student's t-test, two tailed). Means± SEM (n=4). 
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prostaglandin E2 production vere only observed in the presence of 
leukotriene c4 , 10 and 15 minutes after addition. In order to investigate 
whether endogenous prostaglandins were involved in the leukotriene c4 induced 
cyclic AMP generation, the experiment vas repeated in the presence c.q. absence 
of indomethacin in a concentration (10-5 M) which was shown to effectively 
inhibit prostaglandin E2 production. As can be seen in figure 5 absolute values 
differed somewhat between the tvo experiments, directional changes were the 
same. Indomethacin reduced control levels, indicating that endogenous 
prostaglandin production indeed is involved in determining intracellular cyclic 
AMP content. Again leukotriene c4 induced a transient increase after minute 
and a second increase after 15 minutes. Both events did not take place in the 
presence of indomethacin, actually leukotriene c 4 slightly reduced cyclic AMP 
levels (not significant) as compared to control macrophages. The effect of 
indomethacin pretreatment on salbutamol and salbutamol/leukotriene c 4 generated 
cyclic AMP production essentially vas the same. In both situations a prolonged 
increase could be observed. 
% change vs. controls 
+ 
100 
50 
0 
50 
Figure 6. Effects of isobuthylmethylxan-
thine (IBMX) on the LTC4 induced release 
of prostaglandin E2 (PGE2 ). thromboxa-
ne B2 (TxB2 ) ~~d ~-glucuronidase (CUR) 
from carrageenan elicited macrophages. 
Open bars represent values found when no 
IBMX vas added, closed bars the values 
found in the presence of 1o-5 -1o-3 M 
IBMX. IBMX dose-dependently reversed the 
LTC4 induced PGE2 and CUR release. No 
effects vere observed on TxB2 producti-
on. Experimental conditions as described 
in the legend to figure 1. • P<0.01 vs. 
LTC4 induced levels (Student's t-test, 
two tailed). Means ± SEM (n~5). 
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A rise in intracellular cyclic AMP can also be achieved by application of a 
phosphodiesterase inhibitor. Isobutylmethylxanthine (IBMX) in the absence of 
leukotriene c4 , inhibited prostaglandin E2 , thromboxane A2 and ~-glucuronidase 
release. In the presence of leukotriene c4 • IBMX counteracted the enhanced 
prostaglandin E2 and ~-glucuronidase release. No effects were observed on 
thromboxane A2 production (figure 6). The latter phenomenon and the observed 
inhibition of thromboxane A2 production in the absence of leukotriene c4 are in 
contradiction with the results presented in the previous paragraph of this 
chapter. 
The fact that indomethacin inhibited the leukotriene c4 induced cyclic AMP 
generation clearly indicates that this increase was due to formation of 
endogenous prostaglandins. Therefore the conclusion that leukotriene c4 itself 
docs not activate adenylate cyclase seems justified. Also the prolonged 
increase in response to salbutamol after indomethacin pretreatment is not 
difficult to explain. Firstly, as was discussed previously, effects of 
e-adrenoceptor agonists are more pronounced with low intracellular cyclic AMP 
levels197 . Secondly, ao a consequence of indomethacin pretreatment 
thromboxane A2 synthesis is inhibited. It is known that thromboxane A2 
decreases the activity of adenylate cyclase 110 Although this phenomenon has 
not been shown in macrophages but in platelets, the decreased thromboxane A2 
production may account for the observed hypersensitivity to e-adrenoceptor 
stimulation. Thirdly but not so likely. indomethacin is known to inhibit 
phosphodiesterase activity. To obtain such an effect a concentration in the 
order of 10-3 M is required, which is a hundred times as much as the 
concentration presently used. Furthermore. if indomethacin was inhibiting 
phosphodiesterase activitY in the concentration used, it would have reduced 
lcukotricne c 4 induced lysosomal enzyme release as could be observed when using 
IBMX. In chapter 5.3 it has been shown that the same dose of lndomethacin used 
ln the experiments described a~ove augmented the effects of leukotriene c4 . 
~everthcless, since in the previously descri~cd experiments no adenylate cyclase 
activating stimulus was added. we cannot rule out the possibility that 
indomethacin inhibited phosphodiesterase. 
No~e of the aforementioned explanatio~s for the observed prolonged effect 
of salbut~ol can satisfactorily account for the effects found with the 
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combination o£ leukotriene c 4 and salbutamol. Neither cyclic AMP, nor 
thromboxane A2 levels were drastically reduced after application of 
leukotriene c 4 per se. A reduction of phosphodiesterase activity by 
indomethacin, thus augmenting the e££ect o£ salbutamol, cannot explain the 
observed prolongation of enh~~ced cyclic AMP levels in the presence of 
leukotriene c4. Prostaglandin E2 levels were not signi£1cantly di£ferent 
between the various groups treated with indomethacin. Therefore enhancement o£ 
endogenous prostaglandin production, as was found in the absence of 
indomethacin, is not likely to contribute to the observed increase of cyclic AMP 
levels. Since indomethacin abolished the leukotriene c 4 induced cyclic AMP 
generation in the macrophages treated with leukotriene c 4 alone, it vas 
concluded that this effect was due to production o£ endogenous prostaglandins. 
It vas also concluded that leukotriene c 4 itself does not activate adenylate 
cyclase. However, recently it has been reported that leukotrienes induce cyclic 
AMP generation, albeit in different systems. 
Gorman and coworkers reported that acetylglyceryl phosphorylcholine (AGEPC) 
induced neutrophil aggregation which vas coincident with a transient rise in 
cyclic AMP. Pretreatment of the cells with indomethacin potentiated the cyclic 
AMP response. In contrast, a 5-lipoxygenase inhibitor blocked both cyclic AMP 
accumulation and aggregation. These data sUggested the involvement of a product 
o£ the 5-lipoxygenase pathway. In a second experiment it was £ound that 
leukotriene B4 elevated cyclic AMP levels in intact cells and stimulated 
adenylate cyclase activity in neutrophil membrane preparations. Testing an 
adenylate cyclase inhibitor these authors £ound that this drug inhibited 
AGEPC-stimulated cyclic AMP accumulation, whereby neutrophil aggregation vas 
actually enhanced. From these experiments they concluded that leukotriene B4 
and AGEPC (indirectly through leukotriene formation) stimulate neutrophil cyclic 
AMP levels but that the increase in cyclic AMP is not responsible for subsequent 
neutrophil aggregation. Instead, the elevation in cyclic AMP appeared to be 
part of a normal homeostatic mechanism that limits the aggregation response 113 . 
Another paper, presented by Claeson and Feinmark, reports that 
leukotriene B4 stimulated the formation of cyclic AMP, the release o£ lysosomal 
enzymes and the generation of superoxide anions by neutrophils. Preincubation 
o£ the cells with (5S,12S)-diHETE or leukotriene B4 resulted in a dose dependent 
inhibition of leukotriene B4 induced degranulation, without causing parallel 
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changes in the levels of cyclic AMP49 . The authors suggested that multiple 
leukotriene B4 receptors may exist, whereby the leukotriene B4 induced 
degranulation and superoxide anion responses are linked to receptors that arc 
not associated with the cyclic AMP system. 
The fact that leukotriene B4 induces cyclic AMP synthesis in neutrophile 
does not 
macrophages. 
necessarily mean that leukotriene c 4 has the same effect 
However some recent findings, listed below, allow speculation 
in 
on 
the possibility that peptidoleukotrienes indeed affect cyclic AMP metabolism. 
Firstly, there is evidence for multiple receptors for peptidoleukotrienes9 1 . 
Moreover, it has been postulated that leukotrienes act as Ca-ionophores232 . 
Furthermore it is known that leukotriene c 4 induces a respiratory burst in 
macrophages 121 In the light of these findings, the observation that stimulants 
of the oxidative burst activate macrophage adenylate cyclase is of particular 
interest. The elevation of cyclic AMP levels in response to the Ca-ionophore 
A23187 could not be blocked by indomethacin, demonstrating that prostaglandin 
synthesis was not involved38 • 
The results described in the previous paragraphs are indicative for the 
existence of different cyclic AMP pools, of which one ca~ be activated by 
leukotrienes via a specific receptor. However, they still do not offer an 
explanation for the results presently described. For, leukotriene c 4 per se did 
not enhance cyclic AMP levels, merely in the presence of salbutamol increased 
levels of cyclic AMP which were possibly due to leukotriene c 4 could be oberved. 
Recently Burka and associates have shown that stimulants of adenylate cyclase 
inhibited A23187 induced contractions of normal guinea-pig trachea41 This 
effect of A23187 is known to be leukotriene c 4 mediated
218
. Sensitized trachea 
responded differently. Low concentrations of adenylate cyclase stimulants, such 
as isoprenalin and forskolin all enhanced A23187 induced contractions, higher 
concentrations inhibited the response. The authors explained their results by 
activation of different pools of cyclic AMP that partake in either the 
release/contraction processes or 
carlier129 and concluded that 
mechanisms in the trachea. 
in negative feedback. as has been described 
sensitization has altered the modulatory 
As was shown in chapter 6.2 P-adrenoceptor agonists did not inhibit 
macrophage basal secretion, despite the fact that they do enhance cycl~c AMP 
levels. It was also shown that ~-adrenoceptor stimula~ion abolishes the effect 
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o£ a stimulating agent such as leukotriene c 4 , an e££ect which was converse, 
though comparable to the e££ects o£ adenylate cyclase stimulants described in 
the previous paragraph. In light o£ the £acts discussed above, the involvement 
of different cyclic AMP pools in the interaction between leukotriene c 4 and 
salbutamol is proposed. This proposal gains strength by the differences 
observed between the e£fects of salbutamol and IBMX. Both salbutamol and IBMX 
counteracted the leukotriene c 4 induced prostaglandin E2 and E-glucuronidase 
release. Marked differences vere observed in their respective effects on 
thromboxane A2 synthesis. Salbutamol reversed the inhibition induced by 
leukotriene c 4 , IBMX had no effect. However, IBMX inhibited basal 
thromboxane A2 production, a property shared by prostaglandin E2 (vide 
chapter 5). Two agents, both enh~~cing cyclic AMP levels, yet different in 
their effects. Whether salbutamol permits the expression of a specific 
leukotriene c 4 receptor and subsequent activation by leukotriene c 4 of a 
specific cyclic AMP pool or whether leukotriene c 4 permits activation of a 
separate cyclic AMP pool by salbutamol is by no means clear yet. 
4 SUMMARY AND CONCLUSIONS 
The involvement of cyclic AMP in the regulation of macrophage activity was 
studied. For that purpose the effects of E-adrenoceptor agonists and a 
phosphodiesterase inhibitor on the leukotriene c 4 induced release response were 
established. Also, kinetic changes in intracellular cyclic AMP levels after 
exposure of the macrophages to salbutamol and/or leukotriene c 4 were studied. 
Finally it was investigated to what extent endogenous prostaglandins were 
involved in the modulation of intracellular cyclic AMP levels. 
Both the non-selective E-adrenoceptor agonist isoprenalin an~ the selective 
2 2-adrenoceptor agonist salbutamol reversed the leukotriene c 4 induced release 
response. Addition of the non-selective E-adrenoceptor antagonist sotalol or 
the E2-selective antagonist H3525 abolished these effects. Practolol. a 
selective 2 1-adrenoceptor antagonist was without any effect on 
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isoprenalin-leukotriene c4 interaction. In conclusion: activation of 
$ 2-adrenoceptors on macrophages abolishes the leukotriene c4 induced release 
response which consists of enhanced prostaglandin E2 production and 
$-glucuronidase release and inhibition o~ thromboxane A2 synthesis. 
Studies on kinetic changes of intracellular cyclic AMP levels revealed that 
leukotriene c 4 induced a transient increase after 1 minute. ~ollowed by a second 
increment after 15 minutes. Both events disappeared after pretreatment of the 
macrophages with indomethacin, indicating that they were prostaglandin mediated. 
Salbutamol, like leukotriene c 4 , induced a rapid transient cyclic AMP 
generation. However, this event was not inhibited by pretreatment with 
indomethacin. in fact a prolonged increase could be observed. The combination 
of leukotriene c 4 and salbutamol was found to have the most prominent effects on 
cyclic AMP levels. In contrast to the transient increments induced by 
leukotriene c 4 or salbutamol seperately, these substances enhanced cyclic AMP 
levels for as long as 10 minutes if added together. Whereas this interaction 
was likely to be due to a leukotriene c 4 induced prostaglandin E2 production. 
surprisingly it could not be inhibited by indomethacin. Differences were 
observed in the effects on thromboxane A2 production between 2-adrenoceptor 
agonists on the one han~ and the phosphodiesterase inhibitor IBMX and 
prostaglandin E1 on the other side. Leukotriene c 4 induced inhibition of 
thromboxane A2 synthesis could be reversed by $-adrenoceptor stimulation, 
whereas IBMX and prostaglandin E1 reduced thromboxane A2 production. These 
results are discussed in the light of a proposed existence of different cyclic 
AMP pools which can be activated either by leukotriene c 4 or by salbutamol. In 
conclusion: leukotriene c 4 induces a rapid transient cyclic AMP generation 
which is prostaglandin mediated. In contrast, the interaction between 
leukotriene c 4 and salbutamol in modulating cyclic AMP metabolism appears to be 
independent on endogenous prostaglandin production and probably takes place via 
activation o~ separate cyclic AMP pools. 
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SUMMARY AND CONCLUDING REMARKS 
Over ~he las~ ~wo decades considerable advances have been made in 
unders~anding ~he role of macrophages within the body's defence sys~em. 
Originally ~hese cells were characterized as simple scavengers 172 cells which 
adequately phagocytosed and killed bacteria or removed cell debris. A simple 
cell which lacked ~he sophisticated recognition and control mechanisms of the 
cellular elite: lymphocytes. The term -angry- macrophage, previously used to 
denominate activated macrophages, fits the macrophage perfectly if it could have 
realized the position it was relegated to: second-class. Thanks to the 
recognition of its ability to secrete an enormous battery of products77 • 114 • 134 
and its ability ~o present antigens to lymphocytes39 • 186 •250 , the macrophage now 
is placed on the position it deserves: first-class. As was described in 
chapter 1, the macrophage does not only ingest and kill microbes, it selectively 
lysis tumour cclls4 •251 and plays a key role in initiating and modula~ing immune 
reactions101,180_ Because of the fact that the macrophage has such a central 
role within the body's defence system, the mechanisms by which the activity of 
this cell is modulated are of great importance. 
Among the products secreted by macrophages are eicosanoids. Chapter 2 
briefly outlines the biosynthesis, structure and general properties of 
eicosanoids. In chapter 4, more specifically, the production of eicosanoids by 
macrophages is discussed. Macrophages are known to release both cyclooxygenase-
and lipoxygenase-derived arachidonic acid oxygena~ion products206 •239 . In ~he 
experiments described in chapter 4 eicosanoid release was correlated with 
macrophage activity. Comparing three different cell populations it was found 
that ~he production of cyclooxygenase metabolites was inversely correlated tc 
the release of 2-glucuronidase, a lysosomal enzyme. Lysosomal enzyme release in 
a well-estaOlished aspecific indicator of cell activity65 · 225 . Thus. active 
cells showed a reduced capacity to produce cyclooxygenase metaOolites. It could 
also be observed that after in vivo stimulation within the cyclooxygenase 
pathwaj' a st.ift occurred. In co:nparison to th:-omboxane A2 . prostaglandin E2 
prod.uctio:J. was pr-eferentially inhiOi'te:i. ~he release of lipoxygenase 
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metabolites on the other hand was positively correlated to cell activity. 
Resident macrophages, the least active cells, did not release leukotriene c 4 
whereas elicited macrophages did. Furthermore it was observed that carrageenan 
elicited macrophages produced less leukotriene c 4 than Freund's incomplete 
adjuvant elicited macrophages. A similar pattern was found with respect to 
$-glucuronidase release. The facts that prostaglandin E2 production was 
preferentially inhibited and leukotriene c 4 production enhanced after in vivo 
activation provide further proof for the hypothesis that prostaglandin and 
leukotriene synthesis are independently mediated and are indications that these 
metabolites may be crucially involved in regulation of macrophage activity. 
Independent modulation of cyclooxygenase and lipoxygenase activity can be 
explained by the existence of two independent sources of substrate arachidonic 
or the existence of two independently mediated phospholipase A2 
acid21 o 
pools265. Products of the lipoxygenase pathway can have actions on macrophages 
which are opposite to those of the cyclooxygenase pathway. The concept that 
there are multiple, specific sources of arachidonic acid, giving rise to 
lipoxygenase or cyclooxygenase metabolites, is in accordance with the proposal 
that these compounds play an important role in regulating cell activities. 
Table 1. Effects of arachidonic acid oxygenation metabolites/ 
metabolism on macrophage functions. 
macrophage 
function 
!a-antigen expression 
chemiluminescence 
lysosomal enzyme release 
I L-1 secretion 
bactericidal activity 
tumoricidal activity 
proliferation 
thromboplastin production 
plasminogen activator rei. 
+ 
+ 
+ 
cyclooxyg. 
inhibitors 
+ 
o+ 
o+ 
+ 
+ 
+ 
0 
0 
+ 
lipoxyg. 
inhibitors 
The idea that leukotriene c 4 and 
macrophages was sustained by the 
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prostaglandin E2 
results o~ the 
modulate the activity o~ 
experiments described in 
chapter 5. Leukotriene c4 was shown to enhance macrophage activity, expressed 
as lysosomal enzyme release, and to induce the production o~ prostaglandin E2 • 
Prostaglandin E2 in turn was found to inhibit macrophage activity. Further 
proof for the proposed interaction between these two eicosanoids could be found 
in results obtained by other groups. ,, is well documented that 
prostaglandin E2 reduces macrophage activity. Prostaglandin E2 inhibits a.o.: 
chemiluminescence 197 , release of cyclooxygenase products90 , lysosomal enzyme 
release, interleukin I secretion42 and tumoricidal activity176 A more complete 
list of the actions of prostaglandin E2 on diverse aspects of macrophage 
activity is provided in table 1. Less is known about the ef~ects of 
leukotriene c4 on macrophages. Leukotriene c4 induces a respiratory burst
121
, 
enhances prostaglandin E2 production. promotes the release of lysosomal enzymes, 
induces interlcukin I secretion and tumoricidal activity (Bonta, personal 
communication). Interestingly, prostaglandin E2 and leukotrienc c4 have 
opposite effects on all aspects me~tioned. Circumstancial evidence for an 
interaction between cyclooxygenase and lipoxygenasc derived products ca~ be 
found in the opposing effects of inhibition of the respective enzymes on 
macrophage actvity. Ia a~tigen expression a~d interleukin I secretion, for 
example are promoted42 • 156 by cyclooxygenase but inhibited69 • 156 by lipoxygenase 
inhibitors. These two functions are of special importa~ce since they represent 
the major mechanisms by which macrophages regulate lymp~ocyte activity. Thus. 
by influencing macrophages eicosanoids exert profound e~fects on the entire 
imm~~c system. 
Chapter 3 describes what is currently known about adenylate cyclase.how it 
is activated and how cyclic AMP effects are mediated. With ca2+ cyclic AMP is 
considered as a major second messenger, relaying a stimulus from the 
extracellular environment to biochemical machinery within the ce11 17 . Of all 
prostaglandins. prostaglandin E2 was fo~~d to be the most important one 1n 
modulating cyclic AMP levels of macrophages. at least in rats 6 . H~~an 
macrophages are more sensitive to prostacyclin30 Since in the experiments 
described in this dissertation rat macrophages were used and because 
leukotriene c 4 promoted prostaglaridin E2 production from these mac~ophag~s. the 
involvement of cyclic AM? in the leQkotriene c 4 induced releas~ response w~c 
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investigated. 
In order to study cyclic AMP involvement several experiments (described in 
chapter 6) were carried out. Firstly, since adenylate cyclase is not only 
activated by prostaglandin E2 but also by e-adrenoceptor agonists, the e££ects 
o£ these agents on the leukotriene C~ induced release response were studied. 
Secondly, inactivation o£ phosphodiesterase activity leads to accumulation of 
cyclic AMP. There£ore the e££ects o£ the phosphodiesterase inhibitor IBMX were 
assessed. Thirdly, studies on the kinetic changes of intracellular cyclic AMP 
levels were performed in the absence c.q. presence of the cyclooxygenase 
inhibitor indomethacin in order to investigate the contribution of endogenous 
prostaglandins to intracellular cyclic AMP production. 
e-adrenoceptor agonists were found to reverse the leukotriene c 4 induced 
release response. Furthermore, studies whereby diverse agonists and antagonists 
were used, indicated that the ef£ects o£ e-adrenoceptor agonists were mediated 
via activation o£ e 2-adrenoceptors. IBMX also e£fectively reversed the 
leukotriene C~ induced prostaglandin E2 and e-glucuronidase release. However, 
in contrast with the e-adrenoceptor agonists, but, like prostaglandins of the 
E-series, IBMX inhibited thromboxane A2 production. These findings already were 
puzzling but the results obtained £rom the studies on kinetic cyclic AMP changes 
were even more surprising. Leukotriene c 4 as well as salbutamol induced a 
transient increase of cyclic AMP, whereby the leukotriene c 4 induced increment 
was prostaglandin mediated. However, the combination of the two drugs induced a 
cyclic AMP increase which was prolonged. Furthermore, this effect was not due 
to leukotriene c 4 induced prostaglandin production since it could not be blocked 
by indomethacin pretreatment. In contrast, after indomethacin pretreatment the 
e£fect was more pronounced. These results can be explained by the existence of 
several, separate cyclic AMP pools as has been proposed earlier129 . Whether 
such a pool is activated by leukotriene c 4
49 or whether activation of the cell 
by leukotriene c 4 permits stimulation by salbutamol of a specific poo1
41 is far 
from clear. Both situations have been reported earlier, albeit in different 
systems. 
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leukotrienes is reduced after activation. Still the basal release of 
leukotriene c 4 • the 
this 
activating metabolite. is higher in more active cells. The 
reason for discrepancy is not known yet, but this situation might merely 
represent an optimally functioning peptido-leukotriene synthase sytem despite a 
decreased availability of precursor fatty acid. With respect to decreased 
arachidonic acid availability a specific interaction between T lymphocytes and 
macrophages is particularly interesting. T lymphocytes are not capable of 
producing eicosanoids but do provide macrophages with arachidonic acid, which 
can serve as a substrate for the synthesis of eicosanoids106 . This interaction 
may serve as a unique pathway by which the T lymphocyte can modulate the 
activity of the macrophage and by which the macrophage may overcome its impaired 
capacity to produce arachidonic acid oxygenation products. 
The styling of figure was inspired by Francis Picabia's painting: 
-Petite solitude au milieu des soleils-. Picabia gave his painting a subtitle 
which superbly fits the aim of figure 1: -Tableau peint pour raconter non pour 
prouver-. Indeed, the figure is descriptive, not decisive 
model. Oversimplified since ca2+ is 
and only represents 
an oversimplified not included, the 
postulated interaction of leukotriene c 4 with cyclic AMP is deleted and the 
interactions between the different cyclooxygenase metabolites are not 
incorporated. 
unknown-. 
However, according to Picabia -there are no theories about the 
In conclusion, the presently described experiments indicate that: 
- a high degree of macrophage activation is associated with decreased 
production of prostaglandin E2 increased production 
leukotriene c4. 
- leukotriene c 4 promotes macrophage activation, 
leukotriene c 4 promotes prostaglandin E2 production from macrophages. 
- prostagl~~din E2 cannot suppress leukotriene production, 
- prostaglandin E2 suppresses macrophage activity, 
of 
- effects of prostaglandin E2 are mediated via activation of adenylate 
cyclase, 
~2-adrenoceptor stimulation reverses the effects of leukotriene c 4 , 
- effects of ~2 -adrenoceptor agonists are cyclic AMP mediated, but that 
- leukotriene c 4 ~~d salbutarnol interact in enhancing intracellular cyclic 
AMP levels. 
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Finally, it has to be emphasized that lysosomal enzyme release, albeit 
important, is only one aspect of macrophage activity. To check the true 
importance of the proposed interaction between leukotrien~ c4 
prostaglandin E2 other aspects of macrophage activity will have to be studied. 
whereby special attention should be given to those aspects which are involved in 
the cooperation between macrophages and other cells, e.g. lymphocytes. 
Furthermore. as was already mentioned, in human macrophages prostacyclin. 
instead of prostaglandin E2 , is the major suppressive metabolite, Studies which 
are currently carried out in our laboratory indicate that leukotriene D4 is the 
major peptido-leukotriene released by human alveolar macrophages. Obviously, 
much is still to be learned. 
The concept however that macrophage activity is modulated by eicosanoids 
opens broad perspectives in terms of the development of new therapeutical 
agents. Application of drugs. inhibiting the lipoxygenase or the cyclooxygenase 
pathway could result in immunosuppression or enhancement of the immune response 
respectively. Although this approach is quite conventional, combined with 
specific alterations in/on the drugs which renders them tissue selective, such 
agents would be very usefull tools. Possibly. a more specific way to block the 
effects of leukotrienes and prostaglandins can be accomplished by the 
development of selective receptur antagonists. Finally, an approach which has 
attracted little attention consists of reinforcing physiological processes by 
the administration of synthetic analogues. Whereas little doubt exists that a 
succesfull modulation of the imm~~e system would be beneficial for diseases as 
rheumatoid arthritis, AIDS and glomerulonefritis, and although the crucial role 
of macrophages within the immune system nowadays is recognized, the development 
of drugs interfering in macrophage activity still is in its infancy. 
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SAMENVAttiNG EN CONCLUSIES 
Twintig jaar geleden werd de macro~aag nog op eenzel~de manier omschreven 
als aan het begin van deze eeuw door Metchniko~~: een eel die in staat is 
microOrganismen te fagocyteren en vervolgens te doden. Een nuttige eigensehap 
weliswaar, maar, vergeleken met de lymfoeyt, het neusje van de zalm onder de 
cellen van het a!Veer- of immuunsysteem, was de macrofaag een simpele eel. 
Zeals opgesomd in hoofdstuk is deze ~simpele- eel eehter tot veel mecr in 
staat dan alleen de fagocytose van microOrg~~ismen. Zij is betrokken bij de 
vernietiging van kankercellen en speelt een sleutelrol bij het op gang brengen 
van verschillende reacties van het immuunsysteem. De macrofaag is hiertoe in 
staat door twee eigenschappen en wel: (a) haar vermogen diverse. biologisch 
actieve substanties uit te scheiden en (b) het vermogen antigeen aan lym~ocyten 
aan te bieden. Omdat de macrofaag zo'n promincnte positie inneemt in de diverse 
verdcdigingsmcchanismen van het lichaam, is de activiteit va~ deze eel en de 
manier waarop deze activiteit geregeld wordt van groat belang. 
Onder de door macro~agen afgegeven producten, bevinden zich eicosanoiden. 
metabolieten van het meervoudig onverzadigde vetzuur arachidonzuur. Het doel 
van de in de hoofdstukken 4, 5 en 6 van dit proefschrift beschreven studies, was 
het onderzoeken van de afgifte van eicosanoiden door macrofagen en van de 
effecten van eicosanoiden op macrofaag activiteit. Als parameter voor macrofaag 
activitcit werd gckozen voor de afgifte van het lysosomal cnzym 2-glucuronidasc. 
Ecn toegcnomen afgifte van lysosomale enzymen wordt algemeen gcinterpreteerd ale 
ecn tocgenomen activiteit van de eel. Zeals behandeld in hoofdstuk 2 kan 
arachidonzuur omgezet worden in een groat aantal producten, ieder met een 
verschillende biologische werking. Bij de omzetting van arachidonzuur zijn 
verschillende enzymen betrokken, waarvan het cyclooxygenase en het lipoxygenase 
van speciaal belang zijn. Via de cyclooxygenasc route worden ~rostaglandinen en 
thromboxanen gevormd; via de lipoxygenase route ontstaan onder andere de 
leukotrienen. Macrofagen produceren zowel cyclooxygenase als lipoxygenase 
metabolieten. De in hoofdstuk 4 beschreven experimenten hadden tot doel een 
verband te lcggen tussen de activiteit van macrofagen en de afgifte van 
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eicosanoiden. Wanneer een vergelijking wordt gemaakt tussen drie verschillende 
celpopulaties, blijkt dat de productie van cyclooxygenase metabolieten omgekeerd 
evenredig is met de afgifte van het lysosomale enzym $-glucuronidase. Met 
andere woorden, actieve macrofagen 
metabolieten. Voorts bleek dat tussen 
producer en minder 
do verschillende 
cyclooxygenase 
cyclooxygenase 
metabolieten een verschuiving optrad. Bij actieve cellen was de productie van 
zowel thromboxaan A2 als prostaglandine E2 verminderd, waarbij de afgifte van de 
laatste naar verhouding het meest geremd was. Wat de lipoxygenase metabolieten 
betreft was de situatie juist omgekeerd; de minst actieve cellen produceerden 
geen leukotrieen c 4 , terwijl de actieve, opgeroepen macrofagen dit wel deden. 
Deze observaties geven steun aan de al eerder gepostuleerde hypothese dat de 
productie van leukotrienen of van prostaglandinen, hoewel afkomstig v~~ 
hetzelfde vetzuur, onafhankelijk van elkaar geregeld is. Een verklaring voor 
dit verschijnsel kan gevonden worden in het bestaan v~~ meerdere, van elkaar 
onafhankelijke bronnen arachidonzuur of in het bestaan van diverse, op 
verschillende manieren geactiveerde phospholipases A2 . Zeals moge blijken uit 
de volgende alinea hebben lipoxygenase en cyclooxygenase metabolieten 
tegenovergestelde effecten op macrofagen. De hypothese dat er meerdere, 
Tabel 1. Effecten van eicosanoiden/arachidonzuur metabo!isme op 
diverse functies van macrofagen. 
macrofaag PGE 2 LTC 4 cyclooxyg. Iipoxyg. 
functie remmers remmers 
expressie van la-antigeen + 
productie van 0 2 radical en + o+ 
afgifte van lysosomale enz. + o+ 
afgifte van IL-1 + 
bactericide werking 0 + 
tumoricide werking + + 
proliferatie 0 
afgifte v. thrombopiastine 0 
afgifte v. plasminogeen act. + 
- 95 -
specifieke bronnen arachidonzuur bestaan is in overeenstemming met de in deze 
dissertatie geopperde idee dat eicosanoiden een belangrijke rol spelen in de 
regulatie van macrofaag activiteit. 
De resultaten van de experimenten behandeld in hoofdstuk 5. ondersteunen de 
gedachte dat door een interactie tussen leukotrieen c 4 en prostaglandine E2 de 
activiteit van de macrofaag bepaald kan worden. Uit deze experimcnten bleek dat 
leukotrieen c 4 , behalve een toename van de eel activiteit, ook de productic van 
prostaglandinc E2 door macrofagen kan bewerkstelligen. Prostaglandinc E2 
daarentegen remde de activiteit van de eel. Terwijl de in dit proefschrift 
beschreven studies de enige zijn waarbij gekeken werd naar de effecten van zowel 
prostaglandinc E2 als leukotrieen c 4 in een systeem, kan ondersteuncnd bewijs 
voor de voorgestelde intcractie gevonden worden in resultaten, gepubliceerd door 
andere groepen. Deze resultaten hebben vaak betrekking op andere aspecten van 
macrofaag activiteit zeals: zuurstof radicaal productie, interleukin-1 afgifte. 
expressie van Ia-antigeen en tumoricide werking (tabel 1). Zowel uit de studies 
waarbij de metabolieten zelf gebruikt werden, als uit die waarbij de productie 
van de metabolieten geremd werd, kwam naar voren dat cyclooxygenase en 
lipoxygenase metabolieten tegenovergestelde effecten hebben. Bijvoorbeeld: 
interleukin-1 afgifte en Ia-a~tigeen expressie worden geremd door 
prostagl~~dine E2 • echter gestimuleerd na blokkade van de vorming 
prostaglandine E2 door cyclooxygenase remmers. Een omgekeerde situatie was waar 
te nemen met betrekking tot leukotrieen c 4 : stimulatie van beide functies door 
leukotrieen C4 zelf, remming na blokkade va~ de productie van leukotrieen c 4 . 
De bovengenoemde twee functies zijn van bijzonder bela~g. omdat met deze 
functies de belangrijkste manieren genoemd zijn waarmee de macrofaag de 
activiteit van de lymfocyt, en daarmee van het hele immuunsysteem, kan 
bcinvloeden. Concluderend mag dan ook gesteld worden dat eicosanoiden, door 
macrofaag activiteit te bcinvloeden, diepgaande effecten op de werking van hct 
immuunsysteem hebbcn. 
Een bcknopte beschrijving van het enzym adenylaat cyclase, activatie van 
dit enzym en effecten die daardoor teweeggcbracht worden. wordt gegeven in 
hoofdstuk 3. Cyclisch AMP wordt, samcn met ca2+, beschouwd als de bela~grijkste 
intracellulaire -boodschapper-, de stof die er voor zorgt dat een signaal van 
buiten de eel omgezet wordt in een c~ernische reactie binnen de eel. Omdat 
leukotrieen c 4 de afgifte van prostaglandine E2 door macrofagen bevordcrt en 
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omdat bekend was dat de effecten van prostaglandine E2 tot stand komen via 
verhoging van de intracellulaire cyclisch AMP concentratie, werd de rol van 
cyclisch AMP in de interactie tussen beide eicosanoiden onderzocht. Om dit te 
kunnen doen werd een aantal experimenten uitgevoerd (hoofdstuk 6). Daar 
adenylaat cyclase niet alleen door prostaglandine E2 , maar ook door 
~-adrenoceptor stimulatie geactiveerd kan worden, werden als eerste de effecten 
van diverse .s-adrenoceptor agonisten op de werking van leukotrieen c4 
bestudeerd. Vervolgens werd onderzocht wat het resultaat was van ophoping van 
intracellulair cyclisch AMP na inactivatie van het enzym phosphodiesterase door 
IBMX. Tenslotte werd gekeken naar de veranderingen in de tijd van het cyclisch 
AMP gehalte in af- respectievelijk aanwezigheid van de cyclooxygenase remmer 
indomethacine. Deze laatste experimenten werden uitgevoerd om de betrokkenheid 
van de endogeen gevormde prostaglandinen bij de cyclisch AMP generatie te 
bepalen. 
Stimulatie van ~-adrenoceptoren leidde tot remming alle door 
leukotrieen c 4 veroorzaakte effecten. Uit studies met selectieve antagonisten 
bleek dat de effecten van de agonisten tot stand kwamen via stimulatie van 
.s2-adrenoceptoren. Ook 
van prostaglandine E2 
IBMX remde de door leukotrieen c 4 veroorzaakte afgifte 
en .a-glucuronidase. In tegenstelling tot de 
.s-adrenoceptor agonisten, maar evenals prostaglandine E1 , bleek IBMX de 
thrombo:xaan Az_ afgifte te remmen. Een verwarrend resultaat dat er nie't 
duidelijker op werd door de gegevens van de studies naar cyclisch AMP kinetiek. 
Hieruit bleek dat 
een tijdelijke 
veroorzaak'ten. 
zowel leuko'trieen c 4 als de .s2 -adrenocep"tor agonis't salbutamol 
toename van de hoeveelheid intracellulair cyclisch AMP 
De 'toename na leuko'trieen c4 kon geremd worden met 
indomethacine, een gegeven waardoor de conclusie gerech'tvaardigd is dat deze 
toename tot stand kwam via pros'taglandine produc'tie. Werden leukotrieen c 4 en 
salbutamol gezamenlijk gegeven, dan was de cyclisch AMP toename groter en 
bovendien langer aanhoudend. Endogene prostaglandine vorming speelde hierbij 
geen rol; na voorbehandeling met indomethacine was het effect niet verdwenen 
maar juist versterkt. Een verklaring voor di't verschijnsel kan gevonden worden 
in he't bestaan van meerdere, gescheiden bronnen cyclisch AMP. Of een van deze 
bronnen ges'timuleerd wordt door leuko'trieen c 4 , of dat de activatie van de eel 
door leukotrieen c 4 aan salbutamol de gelegenheid biedt een speciale bron aan te 
boren, is geenszins duidelijk. Beide mogelijkheden zijn in de literatuur 
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geactiveerde macrofaag verliest echter, om vooralsnog duistere redenen, haar 
vermogen voldoende prostaglandinen te produceren om een hoog cyclisch AMP 
gehalte in stand te houden. Na activatie daalt dit gehalte razendsnel. Verdere 
activatie van de eel wordt echter voorkomen door de vergrote gevoeligheid van 
het adenylaat cyclase voor prostaglandine E2 • vaardoor 
in staat zijn om de negatieve terugkoppeling in stand 
zelfs kleine hoeveelheden 
te houden. Behalve de 
synthese van prostagla."l-dinen ie ook de capaciteit tot productie van 
leukotrienen. na activatie verminderd. 
leukotrieen c 4 boger in actieve cellen. 
Tech is de basal e af'gifte van 
Hoevel de exacte oorzaak voor deze 
discrepantie niet bekend is, is het heel vel mogelijk dat dit gegeven slechts 
een veerspiegeling is van het feit, dat ondanks verminderde beschikbaarheid van 
arachidonzuur, de moedersubstantie, het leukotrieen genererend enzymsysteem 
optimaal functioneert. Een manier waarop de macrofaag de verminderde 
beschikbaarheid van arachidonzuur op kan vangen ligt besloten in een unieke 
samenverkingsvorm tussen macrofagen en lymfocyten. Zelf is een lymfocyt niet in 
staat eicosanoiden te produceren; vel kan deze eel arachidonzuur af'staan aan de 
macrofaag. die het op haar beurt als substraat voor de eicosanoid productie kan 
gebruiken. Of deze interactie in vivo echter ook optreedt is geenszins 
duidelijk. 
Figuur 1 is gestyleerd naar analogie van Francis Picabia's schilderij: 
Petite solitude au milieu des soleils. Het onderschrift bij dit schilderij 
luidt: ~Tableau peint pour raconter, non pour prouver~, een onderschrift vat 
uitstekend de bedoeling van de figuur veergeeft; niets meer dan de presentatie 
van een simpel model, geen absolute vaarheid. Het model is simpel, immers ca2 + 
is weggelaten. de interactie tussen leukotrieen c4 en cyclisch AMP is er niet in 
opgenomen en wisselwerkingen tussen verschillende cyclooxygenase metabolieten 
zijn niet meegeteld. Volgens Picabia is dit echter gerechtvaardigd. immers: 
-Het onbekende kent geen theorieen~. 
Samenvattend leiden de beschreven resultaten tot de volgende conclusies: 
-verhoogde activiteit van een macrofaag is gecorreleerd aan verminderde 
productie van prostaglandine E2 en toegenomen synthese van leukotrieen c 4 , 
-leukotrieen c 4 bevordert de macrofaag activiteit, 
-leukotrieen c 4 bevordert de af'gifte van prostaglandine E2 door macrofagen, 
-prostaglandine E2 heeft geen effect op de af'gifte van leukotrienen door 
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macro~agen, 
-prostaglandine E2 remt macrofaag activiteit, 
-stimulatie van $ 2-adrenoceptoren doet het ef~ect van leukotrieen c4 op 
macrofagen teniet, 
-effectcn van ~2adrenoceptor agonisten komen tot stand via activatie van 
adenylaat cyclase en 
-er bestaat ecn wisselwerking tussen leukotrieen c4 en salbutamol, leidend 
tot een verhoogd gehalte aan intracellulair cyclisch AMP. 
Ter afsluiting nog enkele kanttekeningen. Hoewel de afgifte van lysosomale 
enzymen cen belangrijke, aspecifieke parameter is van macro~aag activiteit, is 
het maar een facet hiervan. Om de werkelijke betekenis van de vastgestelde 
interactie tussen leukotrieen c4 en prostaglandine E2 te kennen, moeten andere 
aspecten van macrofaag activiteit bestudeerd worden, speciaal die aspecten die 
van belang zijn voor de samenwerking tussen macro~agen en andere cellen. Bij de 
hier beschreven studies werd gebruik gemaakt van ratte-macrofagen. Hoewel we 
nog niet in staat zijn hierovcr een eenduidig oordeel te geven, verschaft het nu 
lopendc onderzoek op onze afdeling ons aanwijzingen dat bij de mens niet 
prostaglandinc E2 , maar prostacycline de belangrijkste cyclooxygenase metaboliet 
is. Voorts is geblcken menselijke longmacrofagen voornamelijk 
leukotrieen D4 producercn. Voordat de hier geopperde hypothese practische 
toepassingen oplevert meet er nog veel onderzocht worden. Echter, het concept 
dat macrofaag activiteit gemodulcerd wordt door eicosanoiden opent een scala aan 
mogelijkheden wat betreft de ontwiYfieling van nieuwe geneesmiddelen. Toepassing 
van ~armaca, die of de lipoxygenase of de cyclooxygenase route remmen, zou 
respecticvelijk een onderdrukking of cen verhoging van de immu~~respons tot 
gevolg kunnen hebbcn. Dezc aanpak is tamelijk conventioncel. GecombineerC 
echter met verandcringen aan de chcmische structuur, zodanig 
genecsmiddelen aangr~Jpen op spccifieke cellen, zou hij leiden tot het ontstaan 
v~~ bijzondcr geschikte, selectief werkzamc farmaca. Een andere manier om de 
werking van leukotrienen en prostaglandinen te remmen houdt de toediening van 
specificke receptor antagonisten in. Tenslotte, versterking van fysiologische 
proccssen door toediening van synthetische analoga is ecn aanpak die. 
onverdiend. nauwelijks a~~dacht geniet. Het staat buiten kijf dat succesvol 
ingrijpen in het immu~~systeem gunstig is bij ziekten zeals rheumatoide 
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arthritis, AIDS en glomerulonefritis. Ook staat vast dat de macrofaag een 
prominente positie inneemt binnen het immuunsysteem. 
gesteld. de ontwikkeling van geneesmiddelen die 
activiteit beinvloeden staat pas in de kinderschoenen~ 
Echter, zoals reeds eerder 
effectief de macrofaag 
2 
3 
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APPENDIX: MATERIALS AND METHODS 
Cell isolation and incubation. 
All cells ve~e isolated from male Wista~ ~ats(175-200 g). Resident 
~eritoneal cells ve~e ha~vested by peritoneal lavage vith 40 ml Gey's Balanced 
Salt Solution (CESS). Elicited cells vere harvested on the fourth day after an 
intrape~itoneal injection vith 2 mg carrageenan (1 mg/ml) (Marine Colloids Inc., 
USA) o~ 2 ml Freund's incomplete adjuvant (Difco Lab .• USA). A cell population 
of more th~~ 90% macrophages, as judged by differential counting of smears 
stained vith May Cr~~vald Giemsa solution, vas obtained by density g~adient 
centrifugation (Lymphoprep, Nyegaard and Co .• Norway). After determination of 
cell viability by Trypan Blue exclusion, the cells vere suspended in Minimal 
Essential Medium, Delbucco's modification (DMEM), supplemented vith penicillin 
(100 IE/ml), streptomycin (0.1 mg/ml) and glutamin (0.292 mg/ml). Trypan Blue 
solution. DMEM, penicillin, st~cptomycin ~~d glutamin all vere purchased f~om 
Flov Lab., USA. Regularly. 1.5 ml of the suspension, containing 2.5x10 6 viable 
' cells/ml, vas incubated for 1.5 hat 37 C in a humidified atmosphere containing 
5% co2 in ai~. In case of the measurements of leukotriene production and cyclic 
AMP content a somevhat different experimental procedure was followed vhich is 
described below in the respective pa~agraphs. 
During the incubation period the cells vere exposed to the following drugs 
or to combinations of these drugs: arachidonic acid {Supelco Inc., USA), A23187 
(Calbiochcm Behring Inc., USA), leukotriene c 4 (a gift from Dr.J.Rokach, Merck 
Frosst Lab., Canada), indomethacin (pharmacie AZR Dijkzigt, The Netherlands), 
aspirin (pharmacie AZR Dijkzigt, The Netherlands), Org 7258) (Organon NV, The 
Netherlands), piroxicam (Pfizer Inc., USA), salbutamol (Claxo, UK), isoprenalin 
(Brocacef, The Netherlands), practolol (ICI, UK), sotalol (Lappe, FRC), H3525 
(dl-erythro-4'-methyl-~(1-isopropylaminoethyl)-benzylalcohol HLL) (a gift from 
Dr.C.Johnsson, AB Hassle, Sweden) and isobuthylmethylxanthine (IBMX) (Janssen 
Chimica, Belgium). Control studies were performed under the same experimental 
conditions and are referred to as basal secretory levels. At the end of the 
PCE2/TxB 2 
pmoles/10 6 MQ. 
CUR (xl 00) /LDH 
mU/l0 6 M¢t . 
• ~~ 200 
if • • 
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Figure 1. Effects of atenolol on there-
lease of prostaglandin E2 ( G), throm-
boxane B2 ( Ill), .a-glucuronidase ( .4..) and 
lactate dehydrogenase ( 0) from carra-
geenan elicited macrophages. Note that 
atenolol was toxic to macrophages as 
could be assessed by the release of lac-
tate dehydrogenase. * P<0.01 vs. 
controls (Student's t-test, two tailed). 
Means± SEM (n~5). 
incubation period the cells were spun down at 12000 g for 1 minute, the 
supernatant was decanted and frozen at -70°C for assay of lactate dehydrogenase 
and .a-glucuronidase 
leukotriene content. 
activity 
Enzyme measurements. 
and prostaglandin E2 , thromboxane A2 and 
Lactate dehydrogenase activity was measured by the method of Wroblesky and 
LaDue2 . In this method lactate dehydrogenase catalyses the conversion of 
pyruvate (Boehringer. FRG) to lactate. whereby NADH (Boehringer, FRG) is used as 
cofactor .. The reduction of NADH concentration can be measured as a declining 
extinction at 340 nm and hence is a parameter for lactate dehydrogenase 
activity. Lactate dehydrogenase release was used as a control parameter. If 
any appreciable changes were observed in the activity of lactate dehydrogenase 
in the incubation medium, suggesting that the membranes of the cells were 
damaged during the test period due to a specific treatment, the effects of this 
treatment were considered to be toxic. An illustration of such an effect is 
provided in figure 1 showing that the .a1-selective adrenoceptor agonist atenolol 
(ICI, UK) was toxic to macrophages. 
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~-glucuronidase activity was quantified using the conversion of 
phenolphthalein glucuronide (Sigma, USA)to phenolpthalein which was then 
measured spectrophotomctrically CA~555 nm). 
standard curve was obtained from Merck, FRC. 
Phenolphthalein used for the 
Measurements of cyclooxygenase products 
thromboxane A2 were Prostaglandin E2 
radioimmunoassay (RIA), whereby thromboxane A2 was 
assayed by a direct 
measured as the stable 
breakdown product thromboxane B2 • Antibodies were obtained from the Institute 
Pasteur (Paris), standard prostagl~~din E2 ~~d thromboxane B2 from Sigma Chern. 
Comp. (USA) and tritiated compounds from the Radiochemical Centre of Amersham 
(~). 
Measurements of 5-lipoxygenase products 
In all experiments whereby leukotriene production was assessed a protocol 
was used ac follows. 10x1o6 macrophagec were suspended in 10 ml DMEM and 
incubated for 15 minutes at 37 C in a humidified atmosphere containing 5~ co 2 in 
air. DMEM was supplemented with glutamin, penicillin and streptomycin as 
described earlier. Additionally gluthathion (2 mM) (Merck, FRG) and arachidonic 
acid (10 
(0.25 mM) 
~g) were added. At the end of the 15 minutes incubation serine 
(Merck, FRG) was added to prevent breakdown of the peptidoleukotrienes 
and the cells were spun down {10 minutes, 1400 g). The pellets vere vashed once 
' vith 10 ml GBSS and the combined supernatants were stored at -70 C. Thereafter. 
prostaglandin B2 (200 ~g) was added as internal standard. The supernatants were 
applied to a couple of Seppak c18 and silica cartridges (Waters/Millipore, The 
Netherlands) which were prewashed with 10 ml ethanol and 10 ml distilled vater. 
The samples were eluted with 4 ml ethanol and evaporated to dryness in a vacuUm 
centrifuge. Dried samples vere dissolved in 0.5 ml of HPLC-solvent A, 
centrifuged and purified by a Millex filter (Waters/Millipore, The Netherlands) 
kept in a HPLC micro vial (Weichmann, Switzerland). Using this 
concentration technique a recovery of 60-70~ regularly could be obtained. 
Reversed phase-HPLC of leukotrienes was carried out on a Nucleosil 5 c18 column 
(Chrompack. The Netherlands) with a 
tetrahydrofuran/methanol/0.1~ (wjv) 
(25/30/45/0.1), adjusted to pH 5.5 with 
solvent system 
EDTA solution in 
ammoniumhydroxide3 . 
(A) as follows: 
water/acetic acid 
A representative 
chromatogram of a leukotriene and prostaglandin 32 standard mixture is shown in 
figure 2A. of a sample in figure 2B (leukotrienes B4 , c 4 , D4 and E4 were gifts 
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Figure 2. HPLC-chromatogram of a mixture of standards (2a) and of a sample (2b) 
containing leukotrienes c4 
leukotrienes c4 , n4 , E4 and 
and B4 . The standard 
B4 each and 40 ng PCB2 . 
mixture contained 100 ng 
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of Dr.J.Rokach. Merck Frosst. Canada). 
Cyclic AMP measurements. 
In order to study kinetic changes of intracellular cyclic AMP contents the 
macrophagcs were preincubated for 15 minutes at 37 C. Preincubation was 
necessary to prevent a -heating effect-, since the cells were kept on ice during 
0 
the isolation and purification procedure. Heating the cells to 37 C causes a 
rise in intracellular cyclic AMP. Following the addition of the different drugs 
the macrophages were allowed to remain in suspension (2.5x10 6 cells/ml, 1 ml) 
for 1, 5, 10 or 15 minutes. IBMX was not added to the incubation medium. After 
the incubation the cells were spun down at 12000 g for 30 seconds and the 
supernatant vas discarded. Following the addition of tris disodium adetate 
(EDTA) buffer (pH 7.4) to the pellet. 5 minutes boiling in a water bath a~d 
centrifugation at 12000 g for minute, the supernatant vas stored at -20 C for 
subsequent cyclic AMP assay. which was carried out by the protein binding 
method1 . 
Statistical evaluation 
Student's t-test (two-tailed) was applied for statistical evaluation of the 
results. 
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